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ABSTRACT
An investigation was undertaken to determine whether Erythrina species indigenous to
South Africa contained the same type of compounds as Erythrina species not found in
South Africa and to determine whether they displayed any anti-inflammatory and anti-
bacterial activity.
Phytochemical analysis was conducted using thin layer chromatography. A great
similarity was found in the leaf profiles of the species being studied. The leaf and bark
extracts of E. caffra and E. Iysistemon appear to have similar profiles when viewed
under normal light and ultraviolet light, (254 and 366 nm). These two species have
similar banding patterns when stained with fast blue reagent for f1avonoids and
potassium hydroxide reagent for coumarins. The five species that were tested appear
to contain alkaloids , flavonoids, coumarins and triterpenes just like the species not found
in South Africa from this genus.
Dried bark and leaves from E. caffra, E. humeana, E. latissima, E. Iysistemon and E.
zeyheri were screened for anti-inflammatory and anti-bacterial activity. Ethanol, ethyl
acetate and water extracts were screened for both anti-inflammatory and anti-bacterial
activity. The cyclooxygenase bioassay was used to test for anti-inflammatory activity.
The ethanol and ethyl acetate extracts generally displayed activity while the water
extracts displayed no activity for both the bark and the leaves. The bark generally
displayed more cyclooxygenase inhibitory activity than the leaves. The bark of E. caffra
and E. Iysistemon displayed the highest cyclooxygenase inhibitory activity .
The disc diffussion bioassay was used to screen for anti-bacterial activity. Anti-bacterial
activity was only detected in the water extracts of the leaves. The water extracts of the
bark showed very little or no activity. The bark yielded more anti-bacterial activity than
the leaves. Anti-bacterial activity was mainly displayed against Gram positive bacteria.
The bark of E. caffra and E. Iysistemon displayed the highest anti-bacterial activity.
Hi
On the basis of the screening results it was decided to use bioasssay guided
fractionation in an attempt to isolate putative anti-inflammatory and anti-bacterial
compounds. A hexane extract from the bark of E. Iysistemon was prepared and purified
using a range of chromatographic methods. Vacuum liquid chromatography, separation
using a chromatotron, thin layer chromatography and high performance liquid
chromatography were used to isolate anti-inflammatory compound(s). The isolation
proved to be unsuccessful as the pure compound had no cyclooxygenase inhibitory
activity. It was subsequently determined that the compounds were lost during the HPLC
procedure.
An ethanolic extract of the bark of E. Iysistemon was purified in an attempt to isolate an
anti-bacterial compound(s). Vacuum liquid chromatography and separation using the
chromatotron was used to purify the crude extract. The more sensitive microtitre
bioassay was used to test for anti-bacterial activity against S. aureus. The isoflavone,
Wighteone was isolated.
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For centuries there has been a conviction in the health profession and academia that
traditional health systems and practices would fade away in modern and industrialized
societies. Unfortunately, or maybe fortunately, traditional healing systems have persisted
alongside the rapidly growing and changing medical establishment. As we enter the 21st
century the major pharmaceutical companies and medical research groups are realising
the enormous potential of indigenous herbs as sources of new drugs.
In South Africa the demand for indigenous medicines and services is considerable
relative to the demand for Western health care services. The dire shortage of doctors
in rural areas has forced inhabitants to consult with traditional healers, if not by choice,
then certainly by necessity (VEALE, FURMAN & OLlVIER, 1992). It is estimated that 27
million consumers in South Africa utilize indigenous medicine and services. Households
in South Africa are spending between 4% and 8% of their annual income on indigenous
medicine and services (MANDER, 1998). From these statistics one cannot dispute the
importance of the traditional healer in South Africa.
A. Traditional Healers
There are three types of traditional healers in South Africa (PANTANOWITZ,1994):
i. Sangoma (diviner) - They are spiritualists providing a link between the living and the
dead. They use the divination of bones;
ii. Nyanga (herbalist) - They use plant extracts as remedjes; and
iii. Mthakathi (sorcerer) - They practice "black magic". They use human tissue for
"muthi" . A popular ingredient is human testis . It is believed to increase the potency of the
"muthi" .
African traditional healers have an elaborate materia medica. They combine the work
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of the clinician and the pharmacist as practised by Western medicinal concepts
(IWU,1993). Traditional healers acquire their knowledge and skills from a family member
or throug h apprenticeship to a renowned practitioner (NYAMWAYA, 1992). Official
herbalists need to be registered. Registration is based on the hereditary chiefs in whose
area the herbalist resides. The registration is covered by the KwaZulu/Natal Act on the
code of the Zulu law; Act 6 of 1981. Registration of herbalists is, however, less effective
now than it was before (CUNNINGHAM, 1988). Registration is seen as an attempt to
control the practice of the herbalist. It is required to show that a herbalist has been
trained by a professional herbalist and also to control the dispensing of herbal remedies.
As much as registration could have a positive effect it does not eliminate the fact that
herbal remedies sometimes have deleterious and harmful effects on patients.
B. Negative aspects of traditional medicine
Diagnosis of an illness by a traditional healer could be problematic. Medical doctors
have the latest medical equipment and have been trained to use it so that they could
make accurate diagnosis. Traditional healers generally do not have any medical
equipment that they can use to make diagnosis. They usually listen to the symptoms that
the patient describes and make inferences from their knowledge about a certain disease
or illness. This is by no means an accurate diagnosis (PANTANOWITZ, 1994).
The dosage of the prescribed medicine could cause a serious problem (NJAU, 1991).
Herbs growing in hot, dry areas have a different concentration of active ingredients from
those growing in wet, cold areas. The age of a particular plant could also influence the
concentration of active ingredients. The traditional healer needs to be aware of this and
also how the environment could influence the concentration of active compounds
(NYAMWAYA, 1992). However, without any scientific training or any other education
how can a traditional healer possibly know this? Some herbs are also extremely toxic,
an increase in dosage beyond a certain point can therefore be fatal. Certain herbs are
toxic but traditional healers are usually not aware of the toxicity. In South Africa toxic
species such as Callilepis laureola (impila) are being dispensed by traditional healers
despite the fact that it is known to have caused 263 reported deaths, 44% of which were
children under the age of 10 years (WAINWRIGHT, SCHONLAND & CANDY, 1977 in
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CUNNINGHAM, 1988).
A number of indigenous procedures involve incisions, scarifications or excisions. The
medical efficacy of these procedures are questionable (PANTANOWITZ, 1994). These
procedures are off course not performed under complete sterile conditions making many
of them very dangerous. Septic infections, trauma due to excessive bleeding and shock
are some of the minor effects that these blood letting procedures could have. The more
serious effects would be the transmission of diseases such as AIDS and in some cases
death (NYAMWAYA, 1992). What is interesting is that most people who have these
procedures performed on them and even the traditional healers who perform them are
unaware of the risks.
The most dangerous practice by traditional healers is the claim that they can cure all
illnesses and diseases, including AIDS. While it is possible that traditional medicine
could have some sort of impact on some illnesses, it is not true that any practitioner
whether it be Western or traditional can cure all illnesses and diseases (O'CONNOR,
1995). These wild claims usually lead to delayed referral for appropriate treatment,
which could have detrimental consequences.
Even though there are a large number of negative aspects to traditional medicine there
are however, also many positive aspects related to traditional medicine.
c. Positive aspects of traditional medicine
Traditional medicine provide inhabitants of rural areas with some form of health care
where Western health care facilities are often lacking (BYE & OUTTON, 1991). In 1982
it was estimated that there is approximately one medical practitioner for every 17 500
people in South Africa (VEALE, FURMAN & OLlVIER,1992). With these statistics it is
clear that traditional medicine should intervene and provide some sort of health care.
To a large number of people illness is not only a physical phenomenon. Social and
spiritual factors are also expected to be involved in illness and disease in some way
(O'CONNOR, 1995). For some people the spiritual and social factors need to be
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addressed and dealt with before complete healing is achieved. In this case the traditional
healer performs rituals and provides a psychological support system for the patient. This
relieves people of their fears and restores their confidence to face life's challenges.
The remedies administered by traditional healers relieves the physical symptoms of
illness. A number of herbal remedies do actually cure the ailment that they are used for.
For example, Joy Veale, a lecturer at the University of the Witwatersrand screened an
extract of Clivia miniata which is used by black South African women to induce labour.
She proved that the Clivia behaved in a similar way as ergometrine, causing
contractions of the uterine muscle (PANTANOWITZ, 1994).
D. Interaction between indigenous and Western forms of health care
There is generally very little interaction between indigenous and Western health care
systems, if any. The interaction that does exist is usually negative. Western medicine
is often considered superior to traditional remedies and the direct use of plants is pushed
into the background (HOSTETTMANN & MARSTON, 1987). There exists a great
amount of intolerance between the two parties for a number of reasons. The
cosmopolitan health care workers are of the impression that traditional healers stop
people from using the Western health care facilities and medicines available to them.
Some traditional healers attempt to build bridges of communication by referring patients
with illnesses that they cannot cure to Western health care facilities (NYAMWAYA,
1992). Western doctors almost always reprimands a patient that admits to having
received traditional health care . Patients are therefore reticent to admit either using or
administering traditional remedies (BYE & DUTTON, 1991).
Ethnobotanists need to throw the light of science on the herbalists art. They need to lay
down a more pragmatic and scientific basis for this practice. If ethnobotanists can carry
out research aimed at laying a firm foundation and a rational scientific basis for herbal
medicine, then maybe cosmopolitan health care systems would have a more positive
attitude towards traditional medicine. If the results of scientific research is readily
available to herbalists through education, interaction and mutual exchange of ideas, then
scientists will be making a very useful contribution to herbal medicine and health care
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· in general. The first step towards developing systems of shared knowledge, use and
benefits is to draw together all information, this is what ethnobotany encompasses.
1.2 ETHNOBOTANY
Ethnobotany can be defined in a number of different ways, i.e. (GIVEN & HARRIS,
1994) :
i. The study of the relationships between people and plants and especially the utilization
of plants by people;
ii. The study of the past and present interrelations of primitive or aboriginal human
societies with the ambient vegetation; or
iii. The study and evaluation of the knowledge of all phases of plant life amongst
primitive societies and the effect of the vegetal environment upon the life, customs,
beliefs and history of the people of such societies.
Ethnobotany is a science which brings cultural awareness of natural resources and is
applied specifically to tribal people.
A. People, plants and culture
The dependance of mankind on plants is as ancient as our evolutionary history. People
have depended on plants to satisfy the needs of daily life; food, shelter, clothing, fuel
and medicines (MCKENNA, 1992). The most important of these uses being food. The
selection of some plants in the past has led to the development of major crops such as
maize, rice, barley, wheat and potato. Some of these crops have become important
staple foods for specific tribes thus becoming a facet of their culture (BALlCK & COX,
1996).
The medicinal properties of plants cannot be overlooked especially in rural areas.
Thousands of plants are used by tribal people for their medicinal properties, for example,
in Samoa some tribes use the bark, roots and meristems of Inocarpus fagifer for
appendicitis, internal distress and inflammation (COX, 1993). In South Africa the Xhosa
people use Hypoxis latifolia for heart complaints, impotency and barrenness (SIMON &
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LAMLA, 1991). The uses stated above are merely examples of traditional medicinal
plants used by tribal people; it is by no means indicative of even the smallest proportion
of plants used by tribal people for their medicinal properties. The number of plants used
for their medicinal properties are endless. COX and BALlCK (1994) stated that 265 000
flowering species grace the earth and less than half of one percent have been studied
exhaustively for their chemical composition and medicinal value. Investigations of the
medicinal properties of plants have revealed and are still yielding compounds which
have applications worldwide.
B. Ethnobotany a multi-disciplinary science
Ethnobotany is truly a multi-disciplinary science that has come of age. It incorporates
biology, plant science, chemistry, history, anthropology, culture and literature. It is
dependant on the close collaboration with the above mentioned disciplines (GIVEN &
HARRIS, 1994). Other essential collaborators who have also been involved in the
ethnobotanical plight are the pharmacists, pharmacologists and ethnopharmacologists.
Ethnobotany has also given rise to the discipline, ethnomedicine. In the case of
ethnomedicine there is a need for the involvement of physicians in field work to assist
with the diagnosis of symptoms treated by medicinal herbs (PRANCE, 1994).
Collaboration can only be achieved through centres of excellence.
c. Ethical issues involved in ethnobotany
A number of ethical issues will always arise when conducting an ethnobotanical study.
The most important of these issues being intellectual property rights. It is easy to
assume that the absence of formal plant rights and patenting for plants means that
anyone is free to obtain information and to use it to their advantage (GIVEN & HARRIS,
1994). Commercial enterprises must recognize the need to share benefits. The benefits
need to be shared with the countries that are the source of genetic resources and more
importantly with the indigenous people (MARTIN, 1995). Intellectual property rights
allows only for the patenting of identified active plant compounds. It does not include the
plant or indigenous information, so indigenous people cannot use it to assure that they
are rewarded for their information. In developed countries indigenous people do have
rights that provide a basis for trade secret protection. This allows pharmaceutical
6
organisations to develop and market products as long as the indigenous people are
properly rewarded (BARTON, 1994). This raises the question; " What is an adequate
reward and who decides on the reward?"
1.3 DRUG DISCOVERY
A. The role of plants in drug discovery
Even though the first chemical substance isolated from plants was benzoic acid in 1560,
it was not until the 18th century that the search for useful drugs started (FARNSWORTH,
1984). A British physician, William Withering in 1785 found that the leaves of Digitalis
purpurea could be used to treat dropsy (COX & BALlCK, 1994). This led to the isolation
of digoxin and digitoxin from this genus (COX, 1994). These compounds along with
other cardiac glycosides isolated from the genus Digitalis are presently prescribed to
thousands of cardiac patients annually. In 1804 morphine was isolated from the dried
latex of Papaver somnifermum L. (opium) (FARNSWORTH, 1984). Many useful drugs
from higher plants have since been discovered.
Plants seem to have served as models for drug development for three reasons
(FARNSWORTH, 1994) :
i. Twenty five percent of all prescription drugs contain active compounds from higher
plants;
ii. Biologically active compounds sometimes have poor pharmacological activity in
humans and in this case these compounds are used as templates for synthetic
modification and or manufacturing; and
iii. Secondary plant metabolites are useful in studying biological systems and disease
processes.
There is presently a number of plant-derived drugs being used throughout the world.
Table 1.3.1 shows some of these drugs.
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Allantoi n Lanatos ide Rescinnamine
Atropine Leurocristine Reserpine
Bromelain a-Lobeline Scillarens A &B
Codeine Morphine Scopolamine






Emetine Protovertarines A &B Tubocuranine
Xanthotoxin
B. Ethnobotanical approach to drug discovery
The ethnobotanical approach to drug discovery is based on the assumption that
indigenous uses of plants offers clues to the biological activities that those plants
display. It is one of several methods that could be used to choose plants for
pharmacological studies (COX & BALlCK, 1994). The ethnobotanical approach has
resulted in three types of drug discovery (COX, 1994) :
i. Unmodified plant products that have actually displayed clinical efficacy, e.g. digoxin;
ii. Unmodified plant products where its use was only remotely suggested by its
indigenous use, e.g. vincristine; and
iii. Synthetic products based on natural products, e.g. aspirin.
Drug development from ethnobotanical leads is a long and ardous procedure but a
number of drugs have been discovered in this manner. While incomplete Table 1.3.2
8
contains at least 50 such drugs.



























































































































































i. Strengths of the ethnobotanical approach :
The ethnobotanical approach is targeted more towards a specific plant species, genus
or family (COX & BALlCK, 1994). A researcher would find that a specific plant is used
for a specific ailment. He would therefore screen plants for biological activity from the
same genus or family. It is also targeted towards specific biological activities. If for
example a researcher is looking for plants that display biological against HIV then he/she
would screen plants that have inhibitory activity against viruses.
The ethnobotanical approach also allows for indigenous knowledge to be passed on,
and to be shared for the benefit of all people.
ii. Limitations of the ethnobotanical approach:
Very few of the compounds that exhibit biological activity in laboratory tests will become
new drugs. Some will be less potent than existing ones and others will prove to be toxic
for human use (COX & BALlCK, 1994). Most of the compounds isolated from plants will
never make it to the drug development process let alone the market.
Drug discovery using the ethnobotanical approach is a time consuming process. It takes
at least 20 years from the beginning to the final product (BYE & OUTTON, 1991).
Needless to say it requires a great deal of money and it is always difficult to find
organizations willing to invest money in such a project.
Traditional healers are very reluctant to share their knowledge. The curative art is kept
with sanctity and secrecy. It is believed that the herbal medicines will lose their potency
if revealed to other people (AOOAE-MENSAH, 1991). It is one of the greatest tragedies
of the twentieth century when knowledge is not shared and recorded for the benefit of
all people.
c. A plant - based drug development program
The process of developing drugs from natural products is a very long, complex and
expensive process (CRAGG, BOYO, CHRISTINI, MAYS, MAZAN & SAUSVILLE, 1996).





For centuries there has been a conviction in the health profession and academia that
traditional health systems and practices would fade away in modern and industrialized
societies. Unfortunately, or maybe fortunately, traditional healing systems have persisted
alongside the rapidly growing and changing medical establishment. As we enter the 21st
century the major pharmaceutical companies and medical research groups are realising
the enormous potential of indigenous herbs as sources of new drugs.
In South Africa the demand for indigenous medicines and services is considerable
relative to the demand for Western health care services. The dire shortage of doctors
in rural areas has forced inhabitants to consult with traditional healers, if not by choice,
then certainly by necessity (VEALE, FURMAN & OLlVIER, 1992). It is estimated that 27
million consumers in South Africa utilize indigenous medicine and services. Households
in South Africa are spending between 4% and 8% of their annual income on indigenous
medicine and services (MANDER, 1998). From these statistics one cannot dispute the
importance of the traditional healer in South Africa .
A. Traditional Healers
There are three types of traditional healers in South Africa (PANTANOWITZ,1994):
i. Sangoma (diviner) - They are spiritualists providing a link between the living and the
dead. They use the divination of bones;
ii. Nyanga (herbalist) - They use plant extracts as remedies; and
iii. Mthakathi (sorcerer) - They practice "black magic". They use human tissue for
"muthi". A popular ingredient is human testis. It is believed to increase the potency of the
"muthi".
African traditional healers have an elaborate materia medica. They combine the work
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of the clinician and the pharmacist as practised by Western medicinal concepts
(IWU, 1993). Traditional healers acquire their knowledge and skills from a family member
or through apprenticeship to a renowned practitioner (NYAMWAYA, 1992). Official
herbalists need to be registered. Registration is based on the hereditary chiefs in whose
area the herbalist resides. The registration is covered by the KwaZulu/Natal Act on the
code of the Zulu law; Act 6 of 1981. Registration of herbalists is, however, less effective
now than it was before (CUNNINGHAM, 1988). Registration is seen as an attempt to
control the practice of the herbalist. It is required to show that a herbalist has been
trained by a professional herbalist and also to control the dispensing of herbal remedies.
As much as registration could have a positive effect it does not eliminate the fact that
herbal remedies sometimes have deleterious and harmful effects on patients.
B. Negative aspects of traditional medicine
Diagnosis of an illness by a traditional healer could be problematic. Medical doctors
have the latest medical equipment and have been trained to use it so that they could
make accurate diagnosis. Traditional healers generally do not have any medical
equipment that they can use to make diagnosis. They usually listen to the symptoms that
the patient describes and make inferences from their knowledge about a certain disease
or illness. This is by no means an accurate diagnosis (PANTANOWITZ, 1994).
The dosage of the prescribed medicine could cause a serious problem (NJAU, 1991).
Herbs growing in hot, dry areas have a different concentration of active ingredients from
those growing in wet, cold areas. The age of a particular plant could also influence the
concentration of active ingredients. The traditional healer needs to be aware of this and
also how the environment could influence the concentration of active compounds
(NYAMWAYA, 1992). However, without any scientific training or any other education
how can a traditional healer possibly know this? Some herbs are also extremely toxic,
an increase in dosage beyond a certain point can therefore be fatal. Certain herbs are
toxic but traditional healers are usually not aware of the toxicity. In South Africa toxic
species such as Callilepis laureola (impila) are being dispensed by traditional healers
despite the fact that it is known to have caused 263 reported deaths, 44% of which were
children under the age of 10 years (WAINWRIGHT, SCHONLAND & CANDY, 1977 in
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CUNNINGHAM, 1988).
A number of indigenous procedures involve incisions, scarifications or excisions. The
medical efficacy of these procedures are questionable (PANTANOWITZ, 1994). These
procedures are off course not performed under complete sterile conditions making many
of them very dangerous. Septic infections, trauma due to excessive bleeding and shock
are some of the minor effects that these blood letting procedures could have. The more
serious effects would be the transmission of diseases such as AIDS and in some cases
death (NYAMWAYA, 1992). What is interesting is that most people who have these
procedures performed on them and even the traditional healers who perform them are
unaware of the risks.
The most dangerous practice by traditional healers is the claim that they can cure all
illnesses and diseases, including AIDS . While it is possible that traditional medicine
could have some sort of impact on some illnesses, it is not true that any practitioner
whether it be Western or traditional can cure all illnesses and diseases (O'CONNOR,
1995). These wild claims usually lead to delayed referral for appropriate treatment,
which could have detrimental consequences.
Even though there are a large number of negative aspects to traditional medicine there
are however, also many positive aspects related to traditional medicine.
c. Positive aspects of tradit ional medicine
Traditional medicine provide inhabitants of rural areas with some form of health care
where Western health care facilities are often lacking (BYE & DUnON, 1991). In 1982
it was estimated that there is approximately one medical practitioner for every 17 500
people in South Africa (VEALE, FURMAN & OLlVIER, 1992). With these statistics it is
clear that traditional medicine should intervene and provide some sort of health care.
To a large number of people illness is not only a physical phenomenon. Social and
spiritual factors are also expected to be involved in illness and disease in some way
(O'CONNOR, 1995). For some people the spiritual and social factors need to be
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addressed and dealt with before complete healing is achieved. In this case the traditional
healer performs rituals and provides a psychological support system for the patient. This
relieves people of their fears and restores their confidence to face life's challenges.
The remedies administered by traditional healers relieves the physical symptoms of
illness. A number of herbal remedies do actually cure the ailment that they are used for.
For example, Joy Veale, a lecturer at the University of the Witwatersrand screened an
extract of Clivia miniata which is used by black South African women to induce labour.
She proved that the Clivia behaved in a similar way as ergometrine, causing
contractions of the uterine muscle (PANTANOWITZ, 1994).
D. Interaction between indigenous and Western forms of health care
There is generally very little interaction between indigenous and Western health care
systems, if any. The interaction that does exist is usually negative. Western medicine
is often considered superior to traditional remedies and the direct use of plants is pushed
into the background (HOSTETTMANN & MARSTON, 1987). There exists a great
amount of intolerance between the two parties for a number of reasons. The
cosmopolitan health care workers are of the impression that traditional healers stop
people from using the Western health care facilities and medicines available to them.
Some traditional healers attempt to build bridges of communication by referring patients
with illnesses that they cannot cure to Western health care facilities (NYAMWAYA,
1992). Western doctors almost always reprimands a patient that admits to having
received traditional health care. Patients are therefore reticent to admit either using or
administering traditional remedies (BYE & DUTTON, 1991).
Ethnobotanists need to throw the light of science on the herbalists art. They need to lay
down a more pragmatic and scientific basis for this practice. If ethnobotanists can carry
out research aimed at laying a firm foundation and a rational scientific basis for herbal
medicine, then maybe cosmopolitan health care systems would have a more positive
attitude towards traditional medicine. If the results of scientific research is readily
available to herbalists through education, interaction and mutual exchange of ideas, then
scientists will be making a very useful contribution to herbal medicine and health care
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· in general. The first step towards developing systems of shared knowledge, use and
benefits is to draw together all information, this is what ethnobotany encompasses.
1.2 ETHNOBOTANY
Ethnobotany can be defined in a number of different ways, Le. (GIVEN & HARRIS,
1994):
i. The study of the relationships between people and plants and especially the utilization
of plants by people;
ii. The study of the past and present interrelations of primitive or aboriginal human
societies with the ambient vegetation; or
iii. The study and evaluation of the knowledge of all phases of plant life amongst
primitive societies and the effect of the vegetal environment upon the life, customs,
beliefs and history of the people of such societies.
Ethnobotany is a science which brings cultural awareness of natural resources and is
applied specifically to tribal people.
A. People, plants and culture
The dependance of mankind on plants is as ancient as our evolutionary history. People
have depended on plants to satisfy the needs of daily life; food, shelter, clothing, fuel
and medicines (MCKENNA, 1992). The most important of these uses being food. The
selection of some plants in the past has led to the development of major crops such as
maize, rice, barley, wheat and potato. Some of these crops have become important
staple foods for specific tribes thus becoming a facet of their culture (BALlCK & COX,
1996).
The med icinal properties of plants cannot be overlooked especially in rural areas.
Thousands of plants are used by tribal people for their medicinal properties, for example,
in Samoa some tribes use the bark, roots and meristems of Inocarpus fagifer for
appendicitis, internal distress and inflammation (COX, 1993). In South Africa the Xhosa
people use Hypoxis latifolia for heart complaints, impotency and barrenness (SIMON &
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LAMLA, 1991). The uses stated above are merely examples of traditional medicinal
plants used by tribal people; it is by no means indicative of even the smallest proportion
of plants used by tribal people for their medicinal properties. The number of plants used
for their medicinal properties are endless. COX and BALlCK (1994) stated that 265000
flowering species grace the earth and less than half of one percent have been studied
exhaustively for their chemical composition and medicinal value. Investigations of the
medicinal properties of plants have revealed and are still yielding compounds which
have applications worldwide.
B. Ethnobotany a multi-disciplinary science
Ethnobotany is truly a multi-disciplinary science that has come of age. It incorporates
biology, plant science, chemistry, history, anthropology, culture and literature. It is
dependant on the close collaboration with the above mentioned disciplines (GIVEN &
HARRIS, 1994). Other essential collaborators who have also been involved in the
ethnobotanical plight are the pharmacists, pharmacologists and ethnopharmacologists.
Ethnobotany has also given rise to the discipline, ethnomedicine. In the case of
ethnomedicine there is a need for the involvement of physicians in field work to assist
with the diagnosis of symptoms treated by medicinal herbs (PRANCE, 1994).
Collaboration can only be achieved through centres of excellence.
C. Ethical issues involved in ethnobotany
A number of ethical issues will always arise when conducting an ethnobotanical study.
The most important of these issues being intellectual property rights. It is easy to
assume that the absence of formal plant rights and patenting for plants means that
anyone is free to obtain information and to use it to their advantage (GIVEN & HARRIS,
1994). Commercial enterprises must recognize the need to share benefits. The benefits
need to be shared with the countries that are the source of genetic resources and more
importantly with the indigenous people (MARTIN, 1995). Intellectual property rights
allows only for the patenting of identified active plant compounds. It does not include the
plant or indigenous information, so indigenous people cannot use it to assure that they
are rewarded for their information. In developed countries indigenous people do have
rights that provide a basis for trade secret protection. This allows pharmaceutical
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organisations to develop and market products as long as the indigenous people are
properly rewarded (BARTON, 1994). This raises the question; 11 What is an adequate
reward and who decides on the reward?"
1.3 DRUG DISCOVERY
A. The role of plants in drug discovery
Even though the first chemical substance isolated from plants was benzoic acid in 1560,
it was not until the 18th century that the search for useful drugs started (FARNSWORTH,
1984). A British physician, William Withering in 1785 found that the leaves of Digitalis
purpurea could be used to treat dropsy (COX & BALlCK, 1994). This led to the isolation
of digoxin and digitoxin from this genus (COX, 1994). These compounds along with
other cardiac glycosides isolated from the genus Digitalis are presently prescribed to
thousands of cardiac patients annually. In 1804 morphine was isolated from the dried
latex of Papaver somnifermum L. (opium) (FARNSWORTH, 1984). Many useful drugs
from higher plants have since been discovered.
Plants seem to have served as models for drug development for three reasons
(FARNSWORTH, 1994):
i. Twenty five percent of all prescription drugs contain active compounds from higher
plants;
ii. Biologically active compounds sometimes have poor pharmacological activity in
humans and in this case these compounds are used as templates for synthetic
modification and or manufacturing; and
iii. Secondary plant metabolites are useful in studying biological systems and disease
processes.
There is presently a number of plant-derived drugs being used throughout the world.
Table 1.3.1 shows some of these drugs.
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Bromelain a-Lobeline Scillarens A &B
Codeine Morphine Scopolamine






Emetine Protovertarines A &B Tubocuranine
Xanthotoxin
B. Ethnobotanical approach to drug discovery
The ethnobotanical approach to drug discovery is based on the assumption that
indigenous uses of plants offers clues to the biological activities that those plants
display. It is one of several methods that could be used to choose plants for
pharmacological studies (COX & BALlCK, 1994). The ethnobotanical approach has
resulted in three types of drug discovery (COX, 1994) :
i. Unmodified plant products that have actually displayed clinical efficacy, e.g. digoxin;
ii. Unmodified plant products where its use was only remotely suggested by its
indigenous use, e.g. vincristine; and
iii. Synthetic products based on natural products, e.g. aspirin.
Drug development from ethnobotanical leads is a long and ardous procedure but a
number of drugs have been discovered in this manner. While incomplete Table 1.3.2
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contains at least 50 such drugs.



























































































































































i. Strengths of the ethnobotanical approach :
The ethnobotanical approach is targeted more towards a specific plant species, genus
or fami ly (COX & BALlCK, 1994). A researcher would find that a specific plant is used
for a specific ailment. He would therefore screen plants for biological activity from the
same genus or family. It is also targeted towards specific biological activities. If for
example a researcher is looking for plants that display biological against HIV then he/she
would screen plants that have inhibitory activity against viruses.
The ethnobotanical approach also allows for indigenous knowledge to be passed on,
and to be shared for the benefit of all people.
ii. Limitations of the ethnobotanical approach:
Very few of the compounds that exhibit biological activity in laboratory tests will become
new drugs. Some will be less potent than existing ones and others will prove to be toxic
for human use (COX & BALlCK, 1994). Most of the compounds isolated from plants will
never make it to the drug development process let alone the market.
Drug discovery using the ethnobotanical approach is a time consuming process. It takes
at least 20 years from the beginning to the final product (BYE & OUTTON, 1991).
Needless to say it requi res a great deal of money and it is always difficult to find
organizations willing to invest money in such a project.
Traditional healers are very reluctant to share their knowledge. The curative art is kept
with sanctity and secrecy. It is believed that the herbal medicines will lose their potency
if revealed to other people (ADDAE-MENSAH, 1991). It is one of the greatest tragedies
of the twentieth century when knowledge is not shared and recorded for the benefit of
all people.
C. A plant - based drug development program
The process of developing drugs from natural products is a very long, complex and
expensive process (CRAGG, BOYO, CHRISTINI, MAYS, MAZAN & SAUSVILLE, 1996).
Figure1.3.1 illustrates the sequential process
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Figure 1.3.1 A plant-based drug development program
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Eryth rina, a member of the family Fabaceae, often arborescent, grows in tropical and
subtropical regions of the world. These trees are frequently referred to as coral trees
because of their red seeds and flowers. Actually the name Erythrina is derived from the
Greek word erythros, meaning red (VAN RENSBURG, 1982). There are approximately
'120 species in existence, six of which are indigenous to South Africa. Of the six South
African species four can be considered trees and two small shrubs.
2.1 SOUTH AFRICAN Erythrina SPECIES
A. Erythrina acanthocarpa
Common name: Tambookie thorn
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Figure 2.1.1 Distribution of E. acanthocarpa (HENNESSY, 1991)
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Figure 2.1.2 Erythrina acanthocarpa
This shrub is usually 1 to 3 m tall and has large, tuberous roots. It does not die back
completely in winter. It sheds all its leaves in winter but the branches live on until they
bud again in spring. The leaves are small and the apical leaflet and the lateral leaflets
are as long as they are broad. The leaves are blue-green in colour and prickles are
.found on the lower rib. This shrub flowers from late September. It produces tightly
packed large spikes of flowers. These spikes can be 170mm long and 150mm wide
(VAN RENSBURG, 1982). The standard petals are vermilion-red, tipped with yellow or
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yellow suffused with green. This colour combination does notoccur in anyother of our
indigenous Erythrina's. Its fruits are distinctive, being heavily armed with prickles. The
seeds are larger than those of ourother species and are brown not red. The fruit itself
, is brown, not blackish as it isforthe other indigenous species. Propagation ismainly by
seed, though cuttings_sometimes set successfully (HENNESSY, 1972).
B. Erythrina caffra
Common names: Lucky bean tree, Cape kaffirboom, urn Sinsi (Zulu)
Erythrina caffra is found inthe Eastern Capeand southern KwaZulu Natal. Itoccurs as
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Figure 2.1.3 Distribution of E. caffra (HENNESSY, 1991)
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Figure 2.1.4 Erythrina caffra
These deciduous trees attain a height of 18m. The bark is grey green to light fawn in
colour, with longitudinal fissures. Thorns are found on the trunk and the branches.
Leaves are trifolate with an apical leaflet slightly larger than the lateral leaves. Both the
apical and lateral leaflets are ovate to elliptical (PALGRAVE, 1977). These trees are
.winter to early spring flowering. The standard petal is usually a brilliant vermillion red,
but there are terracotta, orange and cream coloured varieties too. The stamens of the
flowers are exposed which is what distinguishes it from E. Iysistemon (VAN
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RENSBURG, 1982). The fruit and seeds of E. caffra and E. Iysistemon are
indistinguishable. The clusters of sinuous fruit in the infructescence present an
interesting, Gorgonian appearance in contrast to the poised elegance of the
inflorescences (HENNESSY, 1972).
E. caffra is easily propagated by means of cuttings, truncheons and seeds. It makes a
fine ornamental tree but should not be planted too close to buildings because of its large
. root system. The trees are fast growing and make good shade trees in summer. They
are however not frost tolerant (PALGRAVE, 1977).
C. Erythrina humeana
Common names: Dwarf lucky bean tree, Dwarf kaffirboom, umSinsana (Zulu)
This is a typically coastal species occurring especially along the Northern KwaZulu Natal
coast. It is also found in the Eastern Cape, Mpumalanga, Swaziland and Mozambique
(HENNESSY, 1972).

















. Figure 2.1.5 Distribution of E. humeana (HENNESSY, 1991)
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Figure 2.1.6 Erythrina humeana
These plants are slender graceful shrubswhich attain a height of up to 3 m. They grow
on coastal dunes, rocky outcrops and mountain slopes (VAN RENSBURG, 1982). The
bark is grey and smooth with many thorns. Their shiny, dark green leaves sometimes
look like that of E Iysistemon. Young leaves have tiny hairs but these disappear later.
Main veins and stalks have prickles on them (PALGRAVE, 1977). These shrubs are
summerto autumnflowering, the inflorescencesappearing togetherwiththe leaves. The
standardpetalsare deep scarlet in colour, becoming crimsonwith age;eventhecalices
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calices are red (VAN RENSBURG, 1982). The fruit is very similar in appearance to
those of both E. caffra and E. Iysistemon, albeit a little smaller. The seeds of all three
species are alike in appearance. Plants grow easily from seed but only rarely from
cuttings which must be taken from old wood (HENNESSY,1972).
D. Erythrina latissima
Common names: Broad-leaved lucky bean tree, Cork tree, Broad-leaved coral tree,
um Gqwabagqwaba (ZlLIlu)
This coral tree is very different from the other coral trees; its leaves and flowers are
much larger than that-of the other trees. This tree is probably not as well known as the
other coral trees but is lovely in its own right. The broad-leaved coral tree it is found in
the Eastern Cape, KwaZulu Natal, Mpumalanga, Gauteng, Swaziland and the
Mozambique highlands (VAN WYK, 1972).
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Figure 2.1.7 Distribution of E. latissima (HENNESSY, 1991)
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Figure 2.1.8 Erythrina latissima
The trees are not tall, attaining a height of 5 to 8 m at maturity. They are conspicuous
for their thick grey corky bark and their large grey-green chartaceous leaves. The
flowers are borne during the winter months and the early spring when the trees are
virtually bare of leaves (PALGRAVE, 1977). The inflorescences are a magnificent deep
scarlet colour and the calices are light pink and woolly. The calices are divided into
slender lobes. As the flowers wither their colour changes; the petals shading to crimson
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(HENNESSY, 1972). The fruit is a large woody legume, constricted between the seeds.
It is brownish-black in colour when mature. It opens to reveal a creamy-beige interior.
The seeds, like those of all legumes, are attached alternately near the upper mid-line
of right and left halves of the pod. They have a hard, shiny red testa marked with a black
scar, the hilum scar where they were attached to the pod (VAN RENSBURG, 1982).
Erythrina latissima can be propagated from large truncheons and can be grown from
.seed, It is able to withstand a limited amount of frost. Unfortunately, this species is
nowadays far less common than it was because of man's injudicious use of fire as a
quick and easy means to provide sprig grazing for livestock (HENNESSY, 1972)
E. Erythrina /ysistemon
Common names: Lucky bean tree, Kaffirboom, umSinsi (Zulu)
It is because of its wide distribution and spectacular appearance during its flowering
season, the best known of our erythrina's. It occurs in both low and high rainfall areas
in the Eastern Cape, KwaZulu Natal, Gauteng, Swaziland, Botswana and Zambia (VAN
WYK,1972).
1 14 16 18 20 22 24 26 28 -30 32 34
-::7" -, ---I---~ / p-18 ~ V \ • 18-,
1"'-.'\ • I ..V
zu 1\ ~ r . z ~
\ I----- ) I !
a \ Ir'"
~
~ I n a•
\ V • \ I• •
~4 - \ V • •• ,0::.\ • • I j/-\ -" ~. • ••"1 r----- --- I i ::••• ••--/ : ;!~6 i~ lr' , • ••t I I I ~O





~ • •"j--!- T- --f8- _.- = ~-V :> .:7 ·- r-----:-~! I i ; : I
30'1- ,\ I I ~I~~;l _ -!~+~~ - I . ! ,- -I • ~ -+- . f -;~ -.L . ~I !
~ -c-0 . _-- ~ ~~ - -- - !---+--i-~2- --f-~2
\ - -
-y I
\}- /' i I i ; '1r-~oo • 100 10' 30• --.-./
G4
If tc-.Vl-- I I I i .oJ... '?4
10 12 14 16 18 20 22 24 26 28 30 32 34 36
Figure 2.1.9 Distribution of E./ysistemon (HENNESSY, ·1991)
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Figure 2.1.10 Erythrina Iysistemon
' The taller forms may attain a height of about 10 m, but most trees are only about 6m
tall. The bark is rough, rather dark grey to grey-brown in colour. There are numerous
purplish prickles on the branches. The leaves are trifolate with long stalks and are
arranged spirally near the tips of branchlets (VAN RENSBURG, 1982). It flowers
prolifically during winter and early spring. When the tree is in flower it is normally
leafless. The inflorescences have a more restrained elegance than those of E. caffra.
The bright scarlet flowers are arranged in short, closely-packed conical spikes (VAN
21
WYK, 1993). Pale pink and white variations of the flowers have been seen. The
.standard is never orange coloured . It is very easily propagated from cuttings, truncheons
or seeds (HENNES~Y, 1972).
F. Erythrina zeyheri
Common names: Plough breaker, Break harrow, Ploegbreker, umSinsana (Zulu)
It occurs in the midlands of KwaZulu Natal, the Free State, Lesotho and Gauteng (VAN
RENSBURG, 1982).
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Figure 2.1.12 Distribution of E. zeyheri (HENNESSY, 1991)
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Figure 2.1.12 Erythrina zeyheri
The plough breaker is not a tree but a dwarf shrub. This shrub has a large underground
stem and tuberous roots (hence its common name). The parts of this plant that are
above the ground dies back completely during winter and sprouts again in spring. Large,
trifolate leaves are found on this plant. The leaves are bright green in colour and has
minute hairs. The leaf stalks are armed with prickles on both sides (HENNESSY,1972).
These plants are spring flowering. The inflorescences are borne on long, longitudinally
ridged peduncles, which are themselves often red in colour. The standards are bright
scarlet and are shorter and blunter than those of other species. Because of the
23
acaulescent habit of this species, the only satisfactory means of propagation is from
seeds (VAN RENSBURG, 1982).
2.2 CHEMICAL IMPORTANCE OF THE GENUS Erythrina
Species from this genus have since the early 1900's become the subject of extensive
chemical research. Since the advent of these studies the genus Erythrina has become
very popular for its alkaloids . This greatly stimulated chemical studies. Researchers
have during the process of alkaloidal isolations stumbled on other types of compounds
popular to this genus. These compounds are listed in the Table 2.2.1 .
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Table 2.2.1 Compounds isolated from Erythrina species
FOLKERS et al., (1941)
SCOGIN, (1991)
BARAKAT, et.al., (1977)
BARTON, et al., (1973)
ICHIMARU et al., (1996)
FOLKERS, et al., (1940)
PRELOG, et al., (1973)
FOLKERS, et al., (1940)
GAMES, et al., (1974)
SCOGIN, (1991)
Australia & South Africa
Ervthrina Geographical distribution Compounds isolated References
E. abyssinica Angola, Burundi, Ethiopia, Kenya, Flavonoids :
Malawi, Mozambique, Rwanda, Abyssinone I, 11, Ill, IV, V & VI,
Sudan, Tanzania: Uganda, Zaire, Callistephin, Cristacarpin, Cyanidin
Zambia, Zimbabwe & Mauritius 3-sophoroside, Erythrabyssin I1
Pelargonidin 3-sophoroside
Phasaeollidin & Phaseollin
Abyssinin I, 11 & Ill, Sigmoidin A, B,
C & F & Sigmoidin B 4'-(methyl
ether)


















Erythrina Ge_QQraohicBLdisJribution Comoounds isolated References
FOLKERS et al., (1942)
GHOSAL et al. , (1974)
TIWARI et al., (1979)
FOLKERS et al., (1940)
GHOSAL et al., (1974)
GAMES et al., (1974)
GHOSAL et al., (1974)
FOLKERS, et al., (1940)
ABDULLAH et al., (1979)
AGUILAR, et al., (1981)
FOLKERS et al., (1941)
HARGREAVES et al., (1974)
Bhutan, Burma, China, India &
Nepal
Alkaloids:
Erysodine, Erysoline, Erysopine &
Erysovine
E. americana Mexico Aliphatic natural products:
Hexadecanoic acid , Octadecanoic
acid & Tet radecanoic acid























Ervthrina GeoaraDhical distribution ComDoundsJsolated __References
SCOGIN, (1991)
FOLKERS et al., (1940)
MAILLARD et al., (1987)
HARGREAVES et aI, (1974)
HARGREAVES et al., (1974)
JACKSON et al., (1982)
CHAWLA et al., (1982)
HARGREAVES et al., (1974)













Callistephin, Cyanidin 3-sophoroside SCOGIN, (1991)
& Pelargondin 3-sophoroside
4-0- Methylsigmoidin











Costa Rica, El Salvador,






Ervthrina Geographical distribytion Compoynds isolated References
E. x bidwilli Tanzania, U.S.A. & Fiji Flavonoids :
Chrysanthemin , Cyanidin 3- SCOGIN, (1991)
sophoroside & Pelargonidin
3-sophoroside
Erythrabyssin 11, Bidwilion A & B, IINUMA et al., (1992)
Auriculatin & 8-y, y-Dimethyl-
aliyldaidzein
Alkaloids:
Erybidine, Erysodine, Erythraline HARGREAVES et al., (1974)
(+)-form, Erythrinine &
N-Nororientaline
E. breviflora Michoacan Amino acids & peptides :
Hypaphorine AGUILAR et al., (1993)
Alkaloids:
Erysodine, Erysovine, Erysopine, AGUILAR et al., (1993)
Erythravine & a-Erythroidine
E. brucei Ethiopia & Kenya Alkaloids:
Crystamidine (+)-form, Erythrinine, DAGNE et al. , (1984)
8-0xoerythraline & 8-0xoerythrinine
Erysodine, Erysopine & Erysovine GAMES et al., (1974)
Erythraline (+)-form, Erythratidine & CHAWLA et al., (1985)
11-Methoxyerythratidine
E. burana Ethiopia & Kenya Alkaloids:




Cristacarpin DAGNE et al., (1993)
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HARGREAVES et al., (1974)
SCOGIN, (1991)
CHAWLA et al., (1985)
GAMES et al., (1974)





Ervthrina Geographical distribution Compounds isolated References
E. burtii Kenya & Tanzania Alkaloids:
Erysodine & Erysovine
Flavonoids :





























CHAWLA et al., (1985)
BARAKAT et al., (1977)
Costa Rica, Nicaragua &
Panama
Costa Rica & Colombia
Erythrina Geographical distribytion Compoynds isolated References
a-Erythroidine & I3-Erythroidine
Alkaloids:













Kenya, China, India, Taiwan,
Carribean , Madagascar & French
Guiana
Mexico & U.S.A.
Costa Rica, Panama, Colombia &
Ecuador
Flavonoids :
Callistephin & Pelargonidin 3-
sophoroside
Chrysanthemin & Cyanidin 3-
sophoroside










Amino acids & peptides :
Hypaphorine (S)-form
SCOGIN, (1991)
HARGREAVES et al. , (1974)
HARGREAVES et al., (1974)
SCOGIN, (1991)
HARGREAVES et al. , (1974)
FOLKERS et al., (1941)
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Ervthrina Geographical distribytion Compoynds isolated References
Alkaloids:
Erysodine, Erysonine & Erysopine CHAWLA et al. , (1987)
E. crista-galli Egypt, Ethiopia, Kenya,
Mozambique, Rwanda, Sudan,
Tanzania, Uganda, Zimbabwe,
India, China, Taiwan, Caribbean,
Belize, Costa Rica, El Salvador,
Guatemala, Mexico, Panama,
Mauritius, Seychelles, Argentina,




Docosanoic acid, Eicosanic acid,
Heptadecanoic acid, Hexadecanoic
acid, Octadecanoic acid,












Amino acids & peptides :
Betaine & Hypaphorine (S)-form
Alkaloids:
Cristadine, Crystamidine (+)-form &
N-Noroientaline
Choline, Erysodine, Erysopine,




INGHAM et al., (1980)
IMAMURA et al., (1981)
INGHAM et al., (1980)
MITSCHER et al., (1987)
MITSCHER et al., (1988)
CHAWLA et al., (1987)
DEULOFEU et al., (1947)
CHAWLA et al., (1987)
MANTLE et al., (1984)
WILLlAMAN et al., (1970)
BARAKAT et al., (1977)
NKENEGFACK et al., (1990)
FOLKERS et al., (1941)
GENTILE et al., (1942)
FOLKERS et al., (1941)
BARAKAT et al., (1977)
FOLKERS et al., (1942)
IINUMA et al., (1994)
Caribbean
Namibia
Argentina, Bolivia, Brazil &
Paraguay
Panama, Bolivia, Colombia,




Ervtbrine Geographical distribytion Compoynds isolated References
8-0xoerythrinine DEULOFEU et al., (1947)
Erybidine, Erysotrine, Erythratine &
Erythramine
Cinnamylphenols :
Erycristanols A, B & C
Alkaloids:








Amino acids & peptides :
Hypaphorine (S)-form
Alkaloids:
















NKENGFACK et al., (1997)
NKENGFACK et al., (1995)
NKENGFAGK et al., (1991)
NKENGFACK et al., (1997)
NKENGFACK et al., (1990)
NKENGFACK et al., (1993)
NKENGFACK et al., (1990)
NKENGFACK et al., (1989)
Cameroon, Ivory Coast,
Kenya, Mali, Nigeria, Sudan,
Tanzania, Uganda, Zaire &







A, Erythrinasinate, Abyssinone V,
3'-Prenylnaringenin & 2'-Hydroxy-
5'-methoxybiochanin









313, 21a-diol & 28-acetoxy-
erythrodiol
Pterocarpans :
Erybraedin A, C, D & E,
Isoneorautenol , Gangetinin &
Calopocarpin
Simple aromatic natural products:
H 1 (E) f I t
WANDJI et al., (1990)
exacosy - eru a e
F I




Kenya, Argentina, Bolivia, Brazil,
Chile, Paraguay & Peru
Mexico & U.S.A
Erythrina Geographical distribution Compoynds isolated References
Zambia Flavonoids :
4',5,7-Trihydroxy-6,8-diprenyl FOMUM et al., (1986)
isoflavone
8-Prenylluteone NKENGFACK et al., (1989)
Alkaloids:
Erysodine, Erysopine, Erysovine, FOLKERS et al., (1942)
Erythraline & Erythratidine,
11-0xoerysodine &
11-0xeoerysovine HARGREAVES et al., (1974)
Flavonoids :
Callistephin, Chrysanthemin, GENTILE et al., (1942)
Cyanidin 3-sophoroside &
Pelargonidin 3-sophoroside
Amino acids & peptides :
Hypaphorine (S)-form FOLKERS et al., (1940)
Alkaloids:
Erysodine, Erysopine, Erysovine & FOLKERS et al., (1940)
Erythratidine
Flavonoids :
Callistephin, Cyanidin 3- SCOGIN, (1991)
sophoroside & Pelargonidin 3-
sophoroside
Amino acids & peptides:
Hypaphorine (S)- form FOLKERS et al., (1940)
Alkaloids:





MCKEE et al., (1997)
HARGREAVES et al., (1974)
FOLKERS et al., (1940)
FOLKERS et al., (1944)
HARGREAVES et al., (1974)
FOLKERS et al., (1940)
FOMUM et al., (1986)
Cameroon, Ghana, Nigeria,










Ervthrina Geographical distribytion Compoynds isolated References
E. folkersii Belize, Guatemala, Mexico & Flavonoids :
Hawaii Callistephin, Cyanidin 3- SCOGIN, (1991)
sophoroside & Pelargonidin 3-
sophoroside
Amino acids & peptides :
Hypaphorine (S)-form FOLKERS et al., (1940)
Alkaloids:
Erysodine, Erysoline, Erysonine, HARGREAVES et al., (1974)
Erysopine, Erysotrine, Erysovine &
Erythravine & Erythraline FOLKERS et al., (1940)
Flavonoids :
Cistacarpin & Pelargonidin















E. globocalyx Costa Rica Alkaloids:
Erysodine, Erysopine, Erysovine,
Erythraline (+)-form, a-Erythroidine
HARGREAVES et al., (1974)
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FOLKERS et al., (1940)
FOLKERS et al., (1940)
SCOGIN, (1991)
SCOGIN, (1991)
HARGREAVES et al., (1974)
FOLKERS et al., (1944)
FOLKERS et al., (1940)
HARGREAVES et al., (1974)
Guatemala & Mexico
Caribbean
El Salvador, Guatemala &
Honduras
Pakistan, Mexico & U.S.A
































Kenya, Mozambique, South Africa,
Alkaloids:
Erysodine, Erysovine & Erythraline
Flavonoids :
HARGREAVES et al., (1974)
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Erythrina Geographical distribution Compoynds isolated References
Swaziland &Zimbabwe Callistephin & Pelargonidin SCOGIN, (1991)
3-sophoroside
Alkaloids:






Erysodine, Erysopine & Erysovine HARGREAVES et al., (1974)
E. lanata Indonesia & Mexico Alkaloids:





Costa Rica, Honduras, Nicaragua &
Panama
Botswana, Mozambique, South


















HARGREAVES et al., (1974)
GAMES et al., (1974)
GARCIA-MATEOS et al., (1998)
-----------------
LETCHER et al., (1971)
BARTON et al., (1973)
BARAKAT et al., (1977)
AMER et al., (1991)
GAMES et al., (1974)
SCOGIN, (1991)
MCKEE et al., (1997)




Zimbabwe, India, Sri Lanka,
Australia & Mauritius
Ervthrina Geographical distribution Compoynds isolated References
E. Iivingstoniana Malawi, Mozambique & Zimbabwe Alkaloids:





























GARCIA-MATEOS et al., (1998)
SCOGIN, (1991)
BARAKAT et al., (1977)
DAGNE et al., (1984)
JACKSON et al., (1982)
HARGREAVES et al., (1974)




Ervthrina Geographical distribution Compounds isolated References
Erysotrine & 11-Methoxyerythraline
Erythistemine
El Salvador, Guatemala & Honduras Flavonoids:
Callistephin, Cyandin
3-sophoroside & Pelargonidin 3-
sophoroside
Amino acids & peptides :
Hypaphorine (S)-form
Alkaloids:





Erysopine, Erysotrine & Erysovine
Ethiopia, Kenya, Socotra, Somalia & Alkaloids:
Tanzania Erymelanthine & Erysovine
Alkaloids:















Ivory Coast, Liberia, Nigeria ,
Sierra Leone, Togo, Uganda,
Zaire













Amino acids & peptides :
Hypaphorine (S)-form FOLKERS et al., (1940)
Alkaloids:
Erysodine, Erysopine, Erysothiovine FOLKERS et al., (1942)
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FOLKERS et al., (1944)
HARGREAVES et al., (1974)
BARTON et al., (1973)
JACKSON et al., (1982)
FOLKERS et al., (1940)
FOLKERS et al., (1940)
GAMES et al., (1974)
Comoro Is & Madagascar
Kenya, Nigeria, Sao Tome, Sierra
Leone, Tanzania, Uganda, India,
Indonesia , Caribbean, Costa Rica,
El Salvador, Guatemala, Panama,
Bolivia, Brazil, Colombia, Ecuador,
Peru, Venezuela






























Chrysanthemin & Cyanidin 3-
sophoroside
Alkaloids :
Erysodine, Erysopine & Erysovine
Amino acids & peptides :
Hypaphorine (S)-form
SCOGIN, (1991)
BARAKAT et el., (1977)
FOLKERS et al., (1941)
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FOMUM et al., (1986)
WANDJI et al., (1990)
FOMUM et al., (1986)
FOLKERS et al., (1939)
FOLKERS et al., (1940)
INGHAM et al., (1980)
JACKSON et al., (1982)
HARGREAVES et al., (1974)





Ivory Coast, Liberia, Mali,
Niger, Nigeria, Senegal,
Sierra Leone, Togo &
Mauritius
Erythrina Geographical distribution Compounds isolated References
Alkaloids:
















Erysodine, Erysopine & Erysovine
Simple aromatic products:
Defuscin & Octacosyl (E}-ferulate
Erythrinasinate
Flavonoids :
Auriculatin, 2,3-Dihydroaurisulatin TAYLOR et al., (1986)







FOMUM et et., (1987)
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WANDJI et al., (1995)
WANDJI et al., (1995)
NKENGFACK et al., (1995)
WANDJI et al., (1993)
WANDJI et al., (1995)
WANDJI et al., (1990)
WANDJI et al., (1995)
FOMUM et al., (1985)
FOMUM et al., (1987)
Ervtbcina Geographical distribution Compoynds isolated References




furano (2", 3") isoflavone &
Senegalensin
Erysenegalensein B & C
Erythrisenegalone
Senegalensein
Lupinifolin & Erysenegalensein H & I
Erysenegalensein J & K
Erysenagalensein L & M




Erysotrine, Erysovine, Erythraline, FOLKERS et al., (1941)










FOMUM et al., (1985)
NKENGFACK et al., (1989)
NKENGFACK et al., (1989)
NKENGFACK et al., (1990)
NKENGFACK et al., (1990)
FOMUM et al., (1986)
PROMSATTHA et al., (1986)
NKENGFACK et al., (1993)
NKENGFACK et aI., (1994)
NKENGFACK et al., (1994)
PROMSATTHA et al., (1988)
NKENGFACK et al. , (1989)
PROMSATTHA et al., (1989)
Erythrina Geographical distribution Compounds isolated References
E. sigmoeidia Cameroon, Chad , Guinea, Simple aromatic natural
Ivory Coast, Mali, Nigeria, products:
Senegal, Sudan & Togo Erythrinasinate
Flavonoids :
Abyssinone IV, Sigmoidin F & 5, 7,
4'-Trihydroxy-3'-methoxy-5'-(1"-
prenyl) flavanone













Sigmoidin A, B & C
Sigmoidin D
Sigmoidin G
Sigmoidin I, Corylin &
Neobavaisoflavone
Sigmoidin H, Abyssinone VI,
Phaseollin & Erythrabyssin 11,
Neobavalsoflavone & 6, 8-
diprenylgenstein
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HARGREAVES et al., (1974)
GARCIA-MATEOS et al., (1998)
WILLlAMAN et al., (1970)
GAMES et al., (1974)
NKENGFACK et al., (1994)
FOMUM et al., (1986)
MBAFOR et al., (1997)
KOUAM et al., (1991)
MBAFOR et al., (1997)








Sigmoisides A & B
























E.speciosa Egypt, Brazil & India Flavonoids :
Callistephin, Cyanidin 3- SCOGIN, (1991)
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GAMES et al., (1974)
SINGH et al., (1981)
SINGH et al., (1981)
SINGH et al. , (1981)
HARGREAVES et al., (1974)
HARGREAVES et al., (1974)
Belize, Guatemala & Mexico
Burma, Cambodia, China,
India, Laos, Nepal, Thailand &
Vietnam
Ecvtbrina Geographical distribution Compounds isolated References






























FOLKERS et al., (1939)
SINGH et al., (1981)°
CHAWLA et al., (1985)
MIANA et al., (1972)
SINGH et al., (1981)
SINGH et al., (1975)
SINGH et al., (1981)
CHAUHAN et al., (1987)
SINGH et al., (1975)




Burma, India, Java, Laos,
Moluccas ; Malaysia, Sri





Docosanoic acid, Eicosanoic acid,
Hexadecanoic acid, Octadecanoic
acid & Tetradecanoic acid
Hexacosanoic acid,
1-Hexacosanol,Octacosanol, 1-
Octacosanlol & Tetradecanoic acid
Flavonoids :




















Erythrina Geographical distribution Compounds isolated References
Lanka, Phillippines, Sulawesi , Alkaloids:
Sumatra, Thailand , Vietnam, 2-Epierythratine, Erysodine, GUNATILAKA et al., (1978)
Mauritius, Fiji & Samoa Erysoline, Erysopine, Erysovine,
Erythratine & Erysoflorinone
Erythramine FOLKERS et al., (1939)
E. sykesii Australia & New Zealand Flavonoids :
Callistephin, Cyanidin 3- SCOGIN ; (1991)
sophoroside & Pelargonidin 3-
sophoroside
E. tahitensis Society Is Alkaloids:




E. tajumulcensis Guatemala & Mexico Flavonoids :
Callistephin, Cyanidin 3- SCOGIN, (1991)
sophoroside & Pelargonidin 3-
sophoroside
Alkaloids:
Erysodine, Erysopine, Erysotrine, HARGREAVES et al., (1974)
Erysovine & Erythraline
E. tholloniana Gabon, Nigeria & Zaire Alkaloids:




Egypt, Nigeria, Sao Tome, Principe,
Senegal, Sudan, Tanzania, Uganda,
Burma, Cambodia, China, Hong
Kong, India, Indonesia, Laos,
Malaysia, Phillippines, Sri Lanka,
Taiwan, Thailand, Vietnam,
Australia, New Caledonia, New
Guinea, Caribbean, Belize, El
Salvador, Madagascar, Maldives,
Mauritius, Seychelles, Fiji, Samao,
Tonga & Brazil
Eryth'!na Geographical distribution Compounds isolated References
E. vanegara
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SINGH et al., (1981)
GHOSAL et al., (1972)
GHOSAL et al., (1971)
GHOSAL et al., (1972)
EL-OLEMY et al., (1978)
FOLKERS et al., (1940)
BARTON et al., (1973)
CHAWLA et al., (1988)












































Stachydrine (S)-form & Erythritol
Flavonoids :
Pelargondin
Amino acids & peptides :
Hypaphorine (S)-form
Alkaloids:
Erysodine, Erysovine & Erythraline












ITO et al., (1970)
CHAWLA et al., (1993)
FOLKERS et al., (1940)
FOLKERS et aI, (1940)
FOLKERS et aI, (1940)
SARRAGIOTO et al., (1981)
SARRAGIOTO e1.al., (1981)
GAMES et al., (1974)
GAMES et al., (1974)
2.3 TRADITIONAL USES AND BIOLOGICAL ACTIVITY OF THE GENUS Erythrina
A. Traditional uses
Table 2.3.1 Traditional uses of Erythrina species
Species Plant part Administration Reference
used
E. abyssinica Bark Burnt ash used on wounds. KOKWARO, 1987
Used to treat elephantitis. ICHIMARU et al., 1996
Roots Used to treat malaria and syphilis. ICHIMARU et al., 1996
E. breviflora Flowers Used for insomnia. AGUILAR et al., 1993
E. caffra Leaves Paste used for urinary complaints HUTCHINGS et al., 1996
and venereal diseases.
Infusion used for earache. VAN RENSBURG, 1982
Bark Used for sprains. VAN RENSBURG, 1982
E. costaricensis Leaves Infusion used for menstrual pain. VON REIS et al., 1982
E. humeana Roots Used for sprains, tuberculosis and VAN RENSBURG, 1982
bronchitis.
Bark Burnt ash put onto umbilical cord VAN RENSBURG, 1982
of new born babies.
E. lanceolota Leaves Tea used for kidney problems. VON REIS et al., 1982
E. latissima Bark Ground to a powder and put onto VAN RENSBURG, 1982
open sores.
E. Iysistemon Leaves Clears wounds of maggots. VAN RENSBURG, 1982
Used in childbirth . ROBERTS, 1990
Poultice used for abscesses and HUTCHINGS et al., 1996
swellings.
Bark Used for toothache. ROBERTS, 1990
Ash of burnt bark used to disinfect ROBERTS, 1990
wounds.
Strips used on sore hands. ROBERTS, 1990
Burnt formentation used on VAN RENSBURG, 1982
sprains and strained ligaments.
E. poeppigiana Bark Paste used on strained ligaments. VON REfS et al., 1982
E. sacleuxii Roots Used for gonorrhea. VON REIS et al., 1982
E. senegalensis Leaves Used for gonorrhea and stomach WANDJI et al. , 1995
pains.
E. sigmoidea Bark Used to treat syphil is, wounds and MBAFOR et al., 1997
ulcers.
Used to treat female sterility. MBAFOR et al., 1997
ysed~t 9spgrrbea. ~etab,1~
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- Species Plant part Administration Reference
used I
E. variegata Seeds Used for asthma CHAWLA et al., 1993
Bark Inflammation and viruses. COX et al., 1994
Used as an antiseptic. TELlKEPALLI et al., 1990
Used for the treatment of liver TELlKEPALLI et al. , 1990
disorders .
Leaves Relief of pain in joints . TELlKEPALLI et al., 1990
Used as a diuretic . TELlKEPALLI et al., 1990
E. zeyheri Seeds Used for asthma. VAN RENSBURG, 1982
Leaves Tea used for tuberculosis. VAN RENSBURG, 1982




Most of the studies carried out on the genus Erythrina have been chemical studies. It is
only recently with increased realization of the importance of ethnobotany that
researchers have started testing these plants for biologically active compounds. Table
2.3.2 shows the biologically active compounds that have been isolated. From Table2 .3.2
it is noticeable that no biologically active compounds have been isolated from Erythrina
species indigenous to South Africa.
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Table 2.3.2 Biologically active compounds isolated from Erythrina species
Species ,~ compound Bio'92ica'~tilY _









Bidwillon B & Auriculatin
Auriculatin, n-octaco- sanyl-4-hydroxy-3-
methoxycinnamate & 6,3-diprenyl- genistein







Sigmoidin A & B
Anti-bacterial activity against Fuscobacterium
nucleatum & Prevotella intermedia.
Anti-bacterial activity against Staphylococcus
aureus.
Anti-bacterial activity against Staphylococcus
aureus.
Anti-bacterial activity against Staphylococcus
aureus.
Anti-HIVactivity.
Anti-bacterial activity against Staphylococcus
aureus.
Anti-bacterial activity against Staphylococcus
aureus.
Anti-fungal activity against Aspergillus fumigatus.
Anti-bacterial activity against Staphylococcus
aureus & Micrococcus luteus
IINUMA et al., 1992
KOUAM et al., 1991
NKENGFACK et al., 1995
KOUAM et al., 1991
MCKEE et al., 1997
KOUAM et al., 1991
NKENGFACK et al., 1994
NKENGFACK et al., 1994
BIYITI et al., 1988
E. variegata 4'-hydroxy-3',5'-diprenyl , 3,9-dihydroxy-2,1 0- Anti-inflammatory activity COX, 1995
diprenyl pterocarp-6a-ene and 4'-hydroxy-3',5',_______.fHrjprepY' _
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2.4 AIMS
The aims of this study was basically;
1. To carry out a phytochemical analysis on the bark and leaves of Erythrina species
indigenous to South Africa;
2. To determine if the bark and leaves of the species indigenous to South Africa
displayed any anti-inflammatory and anti-bacterial activity;
3. To extract and isolate the putative anti-inflammatory and anti-bacterial compounds;
and





Plants are solar powered chemical factories that produce both primary and secondary
metabolites. The primary metabolites are compounds needed for, growth and
physiological processes. Secondary metabolites have no obvious roles in a plants
primary metabolism. They are non-nutritive and are not directly essential for growth. It
is thought that these compounds play ecologically significant roles as :
i. Pollinator attractants,
ii. Defensive and protective mechanisms, and
iii. Allelochemicals.
Secondary metabolites are biosynthetically derived from primary metabolites and are
more limited in their occurrence and distribution. They are generally metabolically
expensive to produce and are usually present in much smaller quantities than primary
metabolites.
Some of the types of secondary metabolites found in Erythrina are (Table 2.2.1) :
i. Alkalolda- These compounds are derivatives of tertiary amines while others contain
primary, secondary and quaternary nitrogen (WAGNER, BLADT & ZGAINSKI, 1984);
ii. Flavonoids • These compounds are typical phenolic compounds and are also
conjugated aromatic componds (SWAIN, 1986). The various types of flavonoids differ
in their degree of oxidation of the C ring and in the substitution of the A and Brings
(WAGNER, BLADT & ZGAINSKI, 1984);
iii. Coumarins • A common feature of these compounds is the presence of isoprenoid
chains attached to a carbon or an oxygen atom of the nucleus. The prenyl group is often
found as an epoxide (MURRAY, MENDEZ & BROWN, 1982); and
iv.Triterpenes- These are derivatives of plant sterols (GOODWIN, 1973).
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3.2 MATERIALS AND METHODS
A. Extraction of plant material
Plant material (bark and mature leaves) of E. caffra, E. humeana, E. latissima, E.
Iysistemon and E. zeyheri was collected from the Botany Departmental Garden at the
University of Natal, Pietermaritzburg during February 1998. The plant material was dried
in an oven at 50 QC and stored at room temperature in brown paper bags (bark material
was not available for E. zeyheri). One gram offinely ground plant material was extracted
individually with 10 ml ethanol in an ultrasound bath for 30 min. The extracts were
filtered and dried. The residues were resuspended in ethanol to a final concentration of
25 mg rnl'.
B. Thin layer chromatography
Twenty IJI of each of the plant extracts (25 mg ml") were streaked as 1 cm bands onto
five 20x10 cm plastic Merck silica gel TLC plates. All plates were run in hexane : ethyl
acetate, 2 : 1 (v/v) to obtain separation of compounds. The plates were viewed under
normal and ultraviolet light, 254 and 366 nm. Plates were also sprayed with Dragendorff
reagent (Solution A - 0.85 g basic bismuth nitrate dissolved in 10 ml glacial acetic acid
and 40 ml water under heating. Solution B - 8 g potassium iodide dissolved in 30 ml
water. Solutions A and B are mixed in a 1 : 1 ratio) for detection of alkaloids, fast blue
(3, 3'-Dimethoxybiphenyl-4, 4'-bis(diazonium)-dichloride) reagent (0.5 g fast blue salt
dissolved in 100 ml water) for detection of flavonoids, potassium hydroxide reagent (5%
or 10% ethanolic potassium hydroxide) for detection of coumarins and anisaldehyde-
sulphuric acid reagent (0.5 ml anisaldehyde mixed with 10 ml glacial acetic acid) to
detect triterpenes (WAGNER, BLADT & ZGAINSKI, 1984).
3.3 RESULTS AND DISCUSSION
From Figure 3.3.1 it is evident that there are a number of compounds that are similar in
the leaf extracts amongst the species. There are a few differences amongst the species
but generally the leaf extracts appear to have similar profiles when viewed under normal
light. Under normal light very few compounds are visible in the bark extracts. This is
probably because bark contains fewer pigments than leaves .
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Figure 3.3.1 TLC plate of leaf and bark ethanolic extracts under normal light.
Lanes 1, 3, 5, 7 and 9 are the leaf extracts of E. caffra, E. humeana, E. /atissima,
,E. /ysistemon and E. zeyheri, respectively. Lanes 2, 4, 6 and 8 are the bark
extracts of E. caffra, E. humeana, E./atissima and E./ysistemon, respectively.
Figure 3.3.2 TLC plate of leaf and bark ethanolic extracts under ultraviolet light,
(254 nm). Lanes 1, 3, 5, 7 and 9 are the leaf extracts of E. caffra, E. humeana, E.
/atissima, E. /ysistemon and E. zeyheri, respectively. Lanes 2, 4, 6 ~ md 8 are the
bark extracts of E. caffra, E. humeana, E./atissima and E./ysistemon, repectively.
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Figure 3.3.3 TLC plate of leaf and bark ethanolic extracts under ultraviolet light,
(366 nm). Lanes 1, 3, 5, 7 and 9 are the leaf extracts of E. caffra, E. humeana, E.
latissima, E. Iysistemon and E. zeyheri, respectively. Lanes 2, 4, 6 and 8 are the
bark extracts of E. caffra, E. humeana, E. latissima and E. Iysistemon,
respectively.
The bark extracts appear to contain compounds that are more visible under ultraviolet
light; (254 and 366 nm) (Figures 3.3.2 and 3.3.3) than normal light. The banding pattern
of the bark extract of E. latissima differs a lot from the banding patterns of the bark
extracts of the other species. There seems to be a great similarity in the banding
patterns of E. caffra. and E. Iysistemon in both the bark and leaf extracts when viewed
under ultraviolet light.
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Figure 3.3.4TLC plate of leafand bark ethanolic extracts stained with Dragendorff
reagent. Orange bands indicate the presence of alkaloids. Lanes 1, 3, 5, 7 and 9
are the leaf extracts of E. caffra, E. humeana, E. latissima, E. Iysistemon and E.
zeyheri, respectively. Lanes 2, 4, 6 and 8 are the bark extracts of E. caffra, E.
humeana, E. latissima and E. Iysistemon, respectively.
This genus is known for its alkaloids. As can be seen in Table 2.2.1 such compounds
are present in the species analyzed. Most of the known alkaloids have been isolated
from the seeds, roots and flowers of these plants. From the orange bands in Figure
3.3.4 it is clear that there are a number of alkaloids in both bark and leaf extracts of all
five the species tested. The leaf extract of E. zeyheri appears to contain the most
alkaloids . Again there seems to be a similar banding pattern amongst the species where
the alkaloids seem to be found at or close to the baseline.
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Figure 3.3.5 TLC plate of leaf and bark extracts stained with fast blue (3, 3'-
Dimethoxybiphenyl-4, 4'·bis(diazonium)-dichloride) reagent. Purple bands
indicate the presence of flavonoids. Lanes 1, 3, 5, 7 and 9 are the leaf extracts of
E. caffra, E. humeana, E. lat;ss;ma, E. Iys;stemon and E. zeyher;, respectively.
Lanes 2, 4, 6 and 8 are the bark extracts of E. caffra, E. humeana, E. Ietissim« and
E.lys;stemon, respectively.
From Figure 3.3.5 it is clear that the leaf extracts contained very little or no f1avonoids.
The bark extracts seem to have a large number of fJavonoids. Isolation from the bark
(Lanes 2 and 8) would therefore appear to be a viable venture. The bark extracts of E.
caffra and E. Iysistemon appear to have similar banding patterns. The flowers of these
two species contain the same f1avonoids (Table 2.2.1) it is therefore likely that the bark
extracts of the two species could contain the same f1avonoids. E. latissima and E.
zeyheri appear to have f1avonoids as there is purple discolouration at the baseline but
no flavonoids have ever been isolated from these species (Table 2.2.1).
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Figure 3.3.6 TLC plate of leaf and bark ethanolic extracts stained with potassium
hydroxide reagent. Green flourescensing bands indicates coumarins. Lanes 1, 3,
5, 7 and 9 are the leafextracts of E. caffra, E. humeana, E.latissima, E.lysistemon
and E. zeyheri, respectively. Lanes 2,4,6 and 8 are the bark extracts of E. caffra,
E. humeana, E.latissima and E.lysistemon, respectively.
Table 2.2.1 shows that very few coumarins have been isolated from the genus
Erythrina. Figure 3.3.6 clearly shows that there are quite a number of coumarins
present in this genus. The leaves do not appear to contain any coumarins but the bark
seems to have quite a few. E. caffra and E. Iysistemon appear to contain more
coumarins than any of the other species. They also seem to have similar banding
patterns with respect to these compounds.
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Figure 3.3.7 TLC plate of the leaf and bark ethanolic extracts stained with
anisaldehyde-sulphuric acid reagent. Blue violet colour indicates the presence of
triterpenes. Lanes 1, 3, 5, 7 and 9 are the leafextracts of E. caffra, E. humeana, E.
latissima, E. Iysistemon and E. zeyheri, respectively. Lanes 2, 4,6 and 8 are the
bark extracts of E. caffra, E. humeana, E. latissima and E. Iysistemon,
,respectively.
From the TlC analysis it is clear that very few triterpenes are found in the five species
tested. The bark seems to contain more triterpenes than the leaves. The bark of E.
latissima clearly shows a very distinct presence of triterpenes unlike the bark extracts
of the other species. From Table 2.2.1 it is clear that very few triterpenes have been
isolated from this genus.
3.4 CONCLUSIONS
,Table 2.2.1 revealed that most of the species from the genus Erythrina are chemically
rich plants. It also showed that not many compounds have been isolated from the
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species indigenous to South Africa. This investigation did however, confirm the presence
of alkaloids, flavonoids, coumarins and triterpenes in five of the local species.
This investigation also indicated a great similarity between E caffra and E/ysistemon.
The chemical profiles of these two species appear to be similar in most cases (Figures
3.3.1, 3.3.2, 3.3.3 and 3.3.6). There also appears to be similarities amongst the other
species in the profiles of both the leaf and bark extracts. The profile of the bark extract
of E latissima appears to differ considerably from the other profiles of the bark extracts.
The presence of the various compounds raises a few questions; " What is the purpose
of all these compounds in the plant?". A more important question is; "How can the
presence of these compounds benefit humans and animals in the cycle of life?" and
lastly, "May they serve as a useful chemo-taxonomic tool in the future?".
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CHAPTER FOUR
SCREENING FOR ANTI-INFLAMMATORY ACTIVITY
4.1 INTRODUCTION
A. Inflammation
Inflammation is a mechanism by which protective immune processes can be localized
at a region where infection occurs (VILLEE, SOLOMON, MARTIN, MARTIN, BERG &
DAVIS, 1989). When a pathogen invades mammalian tissue it triggers an array of
responses. Blood vessels in the affected area dilate and increases the flow of blood to
. the infected area. This increased blood flow causes the skin to look red and to feel
warm. Capillaries in the inflamed area become more permeable causi Ag more fluid to
leave the circulation and to enter the tissues. As the amount of interstitial fluid increases
swelling (edema) occurs. This swelling causes pain (ZURIER, 1982). Figure 4.1.1 is a

















Figure 4.1.1 Diagrammatic representation of the inflammation process (VILLEE,
SOLOMON, MARTIN, MARTIN, BERG & DAVIS, 1989)
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B. The biochemical basis of inflammation
Inflammation is induced by prostaglandins. Prostaglandins are the products of the
metabolism of C20 polyenoic fatty acids that contains the five-membered carbon ring.
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Figure 4.1.2 Diagrammatic representation of prostaglandtn synthesis (RANG &
DALE,1987)
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Prostaglandins are synthesized via endoperoxides from arachidonic acid and other
essential fatty acids, The arachidonic acid is converted to endoperoxide PGG2 and via
three different pathways to prostacyclin (PGI2) ; prostaglandins (PGE2 , PGF2 and PGD2;
and thromboxones (A2 and 8 2) (GANONG, 1987).
C. The cyclooxygenase enzymes
Cyclooxygenase is the enzyme involved in the first step of prostanoid synthesis. Two
isoenzymes exist in the mammalian body; the constitutive COX-1 and the inducible
COX-2. These isoenzymes are encoded by two different genes but they produce
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Figure 4.1.3 Diagrammatic representation of the CQX-1 and CQX-2 pathways
(TAKETO, 1998)
The two isoenzymes regulates prostaglandin synthesis. COX-1 is expressed
constitutively and ubiquitously and COX-2 is produced in response to certain stimuli
(TAKETO, 1998). COX-1 produces prostaglandins that are involved in "house-keeping"
activities such as regulating vascular homeostasis, stomach function, renal water and
sodium resorption. COX-2 is not produced in resting tissues and prostaglandins
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produced by this enzyme is probably involved only secondarily in prolonged
physiological reactions (SMITH & DEWITT, 1995).
D. Primary structure of the cyclooxygenase isoenzymes




10 20 30 40 50
2 CTRTGFYGENCSTPEFLTRIKFLLKPTPNTVHYILTHFKGFWNVVNNIPFLRNAIMSYVL
1 CTRTGYSGPNCTIPGLWTWLRNSLRPSPSFTHFLLTHGRWFWEFVNAT-FlREMLMLLVL
60 70 80 90 100 110
·2 TSRSHLIDSPPTYNADYGYKSWEAFSNLSYYTRALPPVPDDCPTPLGVKGKKQLPDSNEI
·1 TVRSNLIPSPPTYNSAHDYISWESFSNVSYYTRILPSVPKDCPTPMGTKGKKQLPDAQLL
120 130 140 150 160 170
·2 VGKLLLRRKF IPDPQGSNMMFAFFAQHFTHQFFKTDHKRGPAFTNGLGHGVDLNH IYGET
1 ARRFLLRRKFIPDPQGTNLMFAFFAQHFTHQFFKTSGKMGPGFTKALGIlGVDLGHIYGDN
180 190 200 210 220 230
2 LARQRKIRLFKDGKMKYQIIDGEMYFPTVKDTQAEMIYPPQVPEHLRFAVGQEVFGLVPG
1 LERQYQLRLFKDGKLKYQVLDGEMYPPSVEEAPVLMHYPRGIPPQSQMAVGQEVFGLLPG
240 250 260 270 280 290
2 LMHYATIWLREHNRVCDVLKQEHPEWGDEQLFQTSRLILIGETIKIVIDDYVQHLSGYHF
1 LMLYATLWLREHNRVCDLLKAEHPTWGDEQLFQTTRLILIGETIKIVIEEYVQQLSGYFL
300 310 320 330 340 350
2 KLKFDPELLFNKQFQYQNRlAAEFNTLYHWHPLLPDTFQINDQKYNYQQFIYNNSILLEH
1 QLKFDPELLFGVQFQYRNRIATEFNHLYHWHPLMPDSFKVGSQEYSYEQFLFNTSMLVDY
360 370 380 390 400 410
2 GITQFVESFTRQIAGRVAGGRNVPPAVQKVSQASIDQSRQMKYQSFNEYRKRFMLKPYES
1 GVEALVDAFSRQIAGRIGGGRNMDHHILHVAVDVlRESREMRLQPFNEYRKRFGMKPYTS
420 430 440 450 460 470
2 FEELTGEKEMSAELEALYGDIDAVELYFALLVEKPRPDAIFGETMVEVGAPFSLKGLMGN
1 FQELVGEKEK~LEELYGDIDALEFYPGLLLEKCHPNSIFGESMIEIGAPFSLKGLLGN
480 490 500 510 520 530
2 VICSPAYWKPSTFGGEVGFQIINTASIQSLICNNVKGCPFTSFSVPDPELIKTVTlNASS
1 PICSPEYWKPSTFGGEVGFNIVKTATLKKLVCLNTKTCPYVSFRVPDASQDDGPAVE---




Figure 4.1.4 Stucture of CQX-1 and CQX-2 (SMITH & DEWITT, 1995)
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COX-1 differs significantly from COX-2 at positions before amino acid residue 30.
Processed COX-1 has 576 amino acids and an N-terminal sequence ADPGA. Mature
COX-2 has an N-terminal sequence ANPCC corresponding to the cleavage of a 17-
amino acid signal peptide. COX-2 contains a cassette of 18 amino acids near the C-
terminus which is absent in COX-1. Although the sequences near the N-termini are
relatively unique, the remaining core sequences of COX-1 and COX-2 are 75% identical
(SMITH & DEWITI, 1995).
E. Inhibitors of the cyclooxygenase enzymes
The main inhibitors of the cyclooxygenase enzymes and hence inflammation are the
non-steroidal anti-inflammatory drugs (NSAID's). These drugs have three major types
of effects; (RANG & DALE, 1987) :
i. Anti-inflammatory effect - Modifying the inflammatory reaction;
ii. Analgesic effect - Reducing pain; and
iii. Antipyretic effect - l owering a raised temperature.
Depending on the dose these NSAID's can have a number of adverse effects. They can
cause gastric upset, delay the birth process and damage the kidneys (TAKETO, 1998).
Based on their binding kinetics with the COX enzymes these NSAID's can be grouped
. into three classes (SMITH & DEWITT, 1995) :
i. Class I NSAID's - These are simple, competitive inhibitors that compete reversibly
with arachidonate for binding to the cyclooxygenase site.
ii. Class 11 NSAID's - These are time-dependant, competitive inhibitors of
cyclooxygenase activity. These agents bind rapidly and reversibly in a first phase to form
an enzyme-inhibitor complex. If retained for a sufficient time in the active site it causes
a conformational change in the protein. Once bound in this tighter form, these time-
dependant NSAID's only slowly dissociate from the cyclooxygense active site.
iii. Class III NSAID's - These are non-competitive inhibitors that bind irreversibly to the
cyclooxygenase active site. Table 4.1.1 contains examples of drugs of all three the
classes.
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Sulindac sulfide (active site of sulindac)
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Class III NSAID's Aspirin
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4.2 MATERIALS AND METHODS
4.2.1 Microsomal isolation
A. Isolation of the cyclooxygenase enzyme
Eight seminal vesicles (approximately 4 cm in diameter) were removed from 1-2 year
old rams at Abakor, the Cato Ridge Abattoir. The vesicles were transported on ice and
then frozen in liquid nitrogen and stored at -70 QC overnight. The frozen vesicles were
cut into small 1x1 cm pieces on a glass petri dish on ice. Sixty five grams of the cut
vesicles was placed into 150 ml 0.1 M potassium phosphate - EDTA buffer, pH 7.4. The
vesicles were ultraturaxed at medium speed for 10 min. The homogenate was then
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placed into an ultrasound bath for 5 min. The homogenate was centrifuged at 4 000 g
(Beckman Avanti J-25 I) for fifteen minutes. The supernatant was decanted and
centrifuged at 17 000 g (Beckman Avanti J-25 1).The microsomes were isolated by
ultracentrifugation at 100000 g (Beckman L7 -5S) for one hour. The microsomal pellet
was resuspended in 0.1 M potassium phosphate buffer, pH 7.8.
B. Determining the enzyme concentration
The enzyme concentration was determined using the Bio-Rad Protein Assay Kit. The
standard procedure was followed except that 20 jJlof each standard or sample solution
were diluted with 1 ml of the dye reagent. The absorbance was read at 595 nm. Once
the concentration had been determined 100 jJl aliquots of the enzyme were pipetted into
Eppendorf tubes and frozen at -70 QC.
C.Optimizing conditions for the enzyme for use in the prostaglandin biosynthesis
bioassay
i. Enzyme concentration
A range of concentrations between 0 and 1% (0, 0.1,0.2,0.3,0.4,0.5,0.6,0.7,0.8,0.9
and 1.0) were used in the the prostaglandin biosynthesis bioassay.
ii. Incubation time
To determine the correct incubation time for the reaction between the substrate
(arachidonic acid) and the enzyme a range of incubation times between 0 and 12 min
(0,3,5,7,9 and 12) were used.
4.2.2 Screening for anti-inflammatory activity
A. Plant material
Plant material (bark and mature leaves) of E caffra, E humeana, E /atissima, E
/ysistemon and E zeyheri was collected from the Botany Departmental Garden at the
University of Natal, Pietermaritzburg during February 1998. A voucher specimen of each
of the five species that was investigated, i.e. E caffra (Pillay2NU), E humeana (Pillay
5NU), E/atissima (Pillay4NU), E/ysistemon (Pillay1NU) and E zeyheri (Pillay3NU) was
deposited in the Herbarium of the University of Natal, Pietermaritzburg.
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B. Extraction of plant material
The plant material was dried in an oven at 50 QC and stored at room temperature in
brown paper bags until further use. One gram of finely ground plant material was
extracted individually with 10 ml ethyl acetate, ethanol or water, respectively, in an
ultrasound bath for 30 min. The extracts were filtered and dried. The residues were
resuspended in ethanol to a final concentration of 20 mg rnl" for the cyclooxygenase
bioassay.
C. Anti-inflammatory activity
Inhibition of prostaglandin biosynthesis by the plant extracts was investigated by using
the cyclooxygenase bioassay. The bioassay was performed according to the method of
WHITE & GLASSMAN (1974) as modified by JAGER, HUTCHINGS & VAN STADEN
(1996).
Cyclooxygenase enzyme solution (4IJg protein prepared from sheep seminal vesicles)
and co-factor solution (0.3 mg rnl' of L-adrenalin and reduced glutathione in 0.1 M Tris
buffer, pH 8.2) was mixed in a 1:5 ratio and incubated on ice for 15 min. Sixty IJI of
enzyme / co-factor solution was added to 17.51J1 water and 2.51J1 ethanolic plant extract
or 2.5 IJI indomethacin standard solution (20 mM). Twenty IJI of 14C_ arachidonic acid
was added to the aqueous samples and incubated at 37 QC for 8 min. The reaction was
terminated by adding 10 IJI 2N HCI. A background sample (17.5 IJI water and 2.51J1
ethanol) was kept in an ice bucket. After incubation 4 IJI of a 2 mg ml" carrier solution
of unlabelled prostaglandins (PGE2 : PGF2 1:1; v/v) was added.
The 14C-labelled prostaglandins synthesised during the assay were separated from
unmetabolized 14C-arachidonic acid by column chromatography. Silica gel in eluent 1
(hexane : dioxan : acetic acid 350 : 150 :1; v/v/v) was packed in Pasteur pipettes to a
height of 3 cm. One ml of eluent 1 was added to each of the assay mixtures and this
mixture was applied to separate columns. The arachidonic acid was eluted with 4 ml of
eluent 1. The prostaglandins were subsequently eluted with 3 ml eluent 2 (ethyl acetate
: methanol 85 : 15; v/v) into scintillation vials. After mixing with scintillation solution, the
radioactivity was counted using a Beckman LS 6000LL scintillation counter. Two
different concentrations of the plant extract (2 and 20 mg rnl" residue) were assayed,
with double determinations for each extract. The percentage inhibition of the test
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solutions was obtained by analysing the amount of radioactivity in these solutions
relative to that present in the solvent blank.
The percentage cyclooxygenase inhibition was calculated using the following formula:
(dpm of sample - dpm of background)
1- (dpm of blank - dpm of background)
X 100
D. Thin layer chromatography
Ten IJI ofthe crude ethyl acetate and ethanol plant extracts (20 mg rnl") of E. caffra, E.
Iysistemon and E. latissima were spotted onto 20x20 cm glass 0.25 mm Merck silica gel
TLC plates. The plates were developed in hexane : ethyl acetate 2:1 (v/v). Spots that
were visible under normal light I ultraviolet light; (254 and 366 nm) and after staining with
4N H2S04 were demarcated. Each spot from a similar non-stained plate was scraped
off separately and the compound eluted with ethanol. The samples were filtered through
0.45 IJm Millipore filters and dried. The residues were resuspended to 20 mg mr' and
2 mg rnl' , respectively and tested for anti-inflammatory activity using the
cyclooxygenase bioassay.
4.3 RESULTS AND DISCUSSION
4.3.1 Microsomal isolation
A. Determining the concentration of the enzyme stock solution
The 10 fold diluted enzyme solution had an absorption of 0.55 at 595 nm. This translates
to a concentration of 0.83 mg rnl" for the diluted solution and 8.3 mg rnl" for the enzyme
solution.
73
1.20.2 0.4 0.6 0.8 1

















<C O~--,--- --.--- -,---.-- -r--------,
Figure 4.3.1.1 Standard curve for the Bio-Rad Protein Assay
B. Optimizing conditions for the enzyme for use in the prostaglandin biosynthesis
bioassay
i. Enzyme concentration
To ensure that the enzyme is saturated during incubation time, normally no more than
30% of the substrate should be converted. On the other hand it is desirable to have as
high counts as possible with the amount of added radioisotope. In the present assay
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Figure 4.3.1.2 Curve to determine the optimal enzyme concentration to use in the
cyclooxygenase bioassay.
From Figure 4.3.1.2 this conversion is obtained with enzyme concentrations of 0.5
mg rnl' to 0.6 mg ml". An enzyme concentration of 0.55 mg rnl' was therefore used in
the bioassay.
ii. Incubation time
The incubation time curve showed an increase in product formation during the first
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Figure 4.3.1.3 Curve to determine the optimal incubation time for the reaction
mixture.
4.3.2 Screening for anti-inflammatory activity
A. Anti-inflammatory activity
The results of the screening for inhibitors of cyclooxygenase are presented in Figure
4.3.2.1 . In general plant material extracted with ethyl acetate and ethanol showed higher
inhibition of cyclooxygenase than did material extracted with water. The water extracts































~ 2mg/ml bark extract
I 20 mg/mlleafextract
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~ 20 mg/ml bark extract
Figure 4.3.2.1 Percentage cyclooxygenase inhibition displayed by a) E. caffra, b)
E. humeana, c) E. latissima, d) E. Iysistemon and e) E. zeyheri. 20 mM
indomethacin displayed an inhibition percentage of 86%.
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The bark extracts generally yielded higher inhibition of cyclooxygenase than the leaves.
This is in agreement with the literature, as it is reported that traditional healers use the
bark more frequently than the leaves to cure certain ailments (Table 2.2.2). COX (1995)
reported that Hedge and Patel isolated anti-inflammatory compounds, two flavanoids;
4'-hydroxy-3',5'-diprenyl and 3,9-dihydroxy-2, 1O-diprenyl pterocarp-6a-ene and a novel
isoflavanone; 4'-hydroxy-3',5',6-triprenyl, from the bark of Erythrina variegata.
E. caffra and E. Iysistemon displayed considerable inhibition of cyclooxygenase. The
ethyl acetate and ethanol extracts of these two species displayed an inhibition of more
than 90% for both the 2 mg rnl" and 20 mg rnl" extracts. This considerable activity at
2 mg ml" is an indication of the presence of very potent compound(s) in the bark of
these two species. E. caffra and E. Iysistemon are the two species most frequently used
by traditional healers (Table 2.2.2).
C. Thin layer chromatography
From the chromatographic results in Figure 4.3.2.2 it is evident that ethyl acetate and
ethanol extract similar compounds. It can also be seen that E. caffra and E. Iysistemon
have very similar chromatographic profiles; indicating that it might be the same
compound(s) in the two species conferring anti-inflammatory activity. The similar
chromatographic profiles is yet another similarity between the two species. E. caffra and
E. Iysistemon was once classified as the same species. Their morphological traits are
almost identical with the only visible difference being in the flowers. In Figure 4.3.2.2 it
is also clear that there are a large number of compounds in E. caffra and E. Iysistemon


















































Ethanol Ethyl acetate Ethanol Ethyl acetate Ethyl acetate
E. caffra E. Iysistemon E. latissima
Figure 4.3.2.2 TLC separation of ethyl acetate and ethanol bark extracts of E.
caffra, E. Iysistemon and E. latissima. Spots with cyclooxygenase inhibition
percentage greater than 80% are indicated in the diagram.
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4.4 CONCLUSIONS
The bark is more active than the leaves for most of the species tested, especially the
bark of E. caffra and E. Iysistemon. The water extracts generally yielded no activity. The
chemical profiles of E. caffra and E. Iysistemon are very similar as indicated in Chapter
three. From the chromatograms it appears that ethanol and ethyl acetate extract the
same types of compounds. Figure 4.3.3 .2 shows that there are a number of compounds
in all three of the species that display significant cyclooxygenase inhibitory activity.
Compound isolation is therefore a viable venture.
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CHAPTER FIVE
ATTEMPTED ISOLATION OF ANTI-INFLAMMATORY
COMPOUNDS FROM THE BARK OF E. Iysistemon
5.1 INTRODUCTION
Although the discovery of new drugs from plants is a taxing process in terms of time and
finance it is a worthwhile long term venture to undertake. From Table 1.3.2 it is clear that
plants are a good source of drugs.
Asprin was one of the first drugs discovered and developed by scientists when the
medicinal properties of plants were being explored (COX & BALCK, 1994). Aspirin is an
anti-inflammatory drug and is one of the most widely used anti-inflammatory drugs in the
world. Even though it has its beneficial effects in the alleviation of inflammation it is not
without its negative effects. One of the greatest negative effects is that it erodes the
lining of the stomach. Most of the other anti-inflammatory drugs have the same effect
on the lining of the stomach. The search for new anti-inflammatory drugs that would not
have these negative effects is without doubt a reason to search for new anti-
inflammatory drugs.
Based on the results of the screening for anti-inflammatory activity of the five Erythrina
species it seemed logical to pursue the isolation of anti-inflammatory compounds from
the bark of E. Iysistemon.
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5.2 MATERIALS AND METHODS
In an attempt to isolate active compounds bioassay guided fractionation was carried out.
The flow diagram below is a summary of the methods used in the purification process.










High pressure liquid chromatography
Figure 5.2.1 Flow diagram of methods used in compound isolation
A. Bulk extraction
One kg of dried bark of E. Iysisfemon was cut into 1x1 cm pieces. These pieces of bark
were placed into a Soxhlet apparatus and extracted with 2.5 I of hexane for 30 hours.
B. Vacuum liquid chromatography
Three grams of the hexane extract was dried under vacuum and placed onto a Merck
silica (150 g) vacuum column (30x6cm). Compounds were eluted with 400 ml
hexane : ethyl acetate. A solvent gradient was used consisting of 100% : 0% to
0% : 100% (v/v) hexane : ethyl acetate, in 5% steps. Four hundred ml fractions were
collected and dried under a vacuum. The residues were resuspended to 20 mg ml" and
tested for cyclooxygenase inhibitory activity using the cyclooxygenase bioassay
(Chapte r 4 for protocol). Ten 1..11 of each fraction was spotted onto a 20x10 cm plastic
Merck silica gel TLC plate. The plate was developed in hexane : ethyl acetate
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2 : 1 (v/v).
C. Chromatotron
The fraction that displayed the highest cyclooxygenase inhibitory activity was dried
undervacuum. The residuewas placedonto a 2 mm chromatotron plate.The platewas
developed in a solvent gradient consisting of 100% : 0% to 70% :30% (v/v) hexane :
ethyl acetate, in 10% steps. The total volume of the solvent mixture was 100 ml. The
bands that were visible at 254 and 366 nm were collected as separate fractions. These
fractionswere dried under vacuum. The residues were resuspended to 20 mg rnl" and
tested for cyclooxygenase inhibitoryactivity using the cyclooxgenase bioassay. Ten IJI
of each fraction was spotted onto a 20x10 cm plastic Merck silica gel TLC plate. The
plate was developed in hexane : ethyl acetate 2 : 1 (v/v).
D. Vacuum liquid chromatography using a small column
The fraction that displayed the highest cyclooxygenase inhibitory activity was dried
under a vacuum. This residue was placed onto a Merck silica (25 g) vacuum
column(17x3cm). Compounds wereelutedwith 100ml hexane : ethyl acetate.A solvent
gradient was used consisting of 100% : 0% to 0% : 100% (v/v) hexane : ethyl acetate,
in 5% steps. One hundred ml fractions were collected and dried under a vacuum. The
residues wereresuspended to4 mgml" and testedfor cyclooxygenase inhibitoryactivity
using the cyclooxygenase bioassay. Ten IJI of each fraction was spotted onto a 20x10
cm plasticMercksilicagel TLC plate.The platewas developedin hexane : ethyl acetate
2 : 1 (v/v).
E. Thin layer chromatography
One hundred miligrams of the fraction that displayed the highest cyclooxyqenase
inhibitoryactivitywas dried undervacuum. The residuewas resuspended in a minimum
amountof ethanoland streaked onto five 20x20cm glass 0.25 mm Mercksilicagel TLC
plates. These plates were run in toluene : ethyl acetate 3 : 1 (v/v). The plates were
viewed under normal and ultraviolet light, (254 and 366 nm). The visible bands were
demarcated andeach bandwas scraped off separately. The compound(s) in each band
was eluted with ethanol. The sampleswere filtered through celite to remove the silica.
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Each sample was dried and the residue resuspended to 4 mg rnl". These samples were
tested for cyclooxygenase inhibitory activity using the cyclooxygenase bioassay.
F. High pressure liquid chromatography
Samples that displayed the highest cyclooxygenase inhibitory activity were purified
further on a Varian (5000) HPLC. These samples were run separately on a C-18 semi-
preparative Phenomenex column (250x10 mm) in 80% : 20% (v/v) methanol: water.
The different compounds present in the samples were detected with a uv 3000HR
detector at 200 nm. The flow rate was 2.5 ml min' and fractions were collected at 1 min
intervals. These fractions were then tested for cyclooxygenase inhibitory activity. The
area or peak that displayed the highest cyclooxygenase inhibitory activity was collected.
G. Testing the lack of activity in samples I and J
Fractions I and J were run separately on a C-18 semi-prepreparative Phenomenex
column (250x10 mm) in 80% : 20% (v/v) and 100% : 0% (v/v) methanol: water. Unlike
before fractions were not collected. The entire samples were collected. These samples
were dried and the residues were resuspended to 4 mg ml". They were then tested for
cyclooxygenase inhibitory activity.
5.3 RESULTS AND DISCUSSION
A. Vacuum liquid chromatography
From Table 5.3.1 it is evident that fractions 0, E, F, G, I, J and K displayed considerable
cyclooxygenase inhibitory activity at 20 mg rnl",
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Table 5.3.1 Cyclooxygenase inhibitory activity displayed by fractions from the
vacuum column.
Fractions Mass of residue % Inhibition at % Inhibition at




0 540 99 93
E 270 100 88
F 290 100 80
G 160 100 79
H 160 89
60 100 79
J 20 100 76




At 2 mg rnl" fraction 0 displayed the highest cyclooxygenase inhibitory activity. The
activity displayed by fraction 0 was higher than that of indomethacin indicating the
presence of a very potent compound in this fraction. The compounds in fraction 0
(Figure 5.3.1) also seem to separate out quite easily in a hexane : ethyl acetate solvent
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Figure 5.3.1 TLC plate of fractions from the vacuum column
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Figure 5.3.1 shows that each of the fractions that was eluted from the column contained
different compounds. There are, however, some overlaps where the same spot would
appear in different fractions. These spots would probably be found in varying
concentrations in the different fractions.
B. Chromatotron
From Table 5.3.2 it is clear that fractions Band C displayed the highest cyclooxygenase
inhibitory activity of all the fractions that were collected and tested, however, fractions
A, B, C and 0 contain the same compounds (Figure 5.3.2). The lower inhibitory activity
of fractions A and 0 could possibly be because of a decrease in concentration of the
active compound. These four fractions were therefore combined and purified further on
a small vacuum column.
Table 5.3.2 Cyclooxygenase inhibitory activity displayed by fractions from the
chromatotron.
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Figure 5.3.2 TLC plate of fractions from the chromatotron
C. Vacuum liquid chromatography using a small column
Fractions I, J, K, M, N, 0 and P all displayed a considerable amount of anti-inflammatory
activity at 4 mg rnl" and were therefore diluted to 0.25 mg ml" and tested for anti-
inflammatory activity. A further dilution to 0.025 mg ml' revealed that fraction 0 was the
most active.
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Table 5.3.3 Cyclooxygenase inhibitory activity displayed by fractions from a small
vacuum column.
Fractions Mass of % Inhibition at . % Inhibition at % Inhibition at










J 40 95 93 25
K 50 96 92 17
L 90 79
M 20 98 97 27
N 380 93 69
0 100 98 98 82
p 10 92 54
Indomethacin 88 84 90
Fraction 0 was very active considering the percentage cyclooxygenase inhibitory activity
of 82% at a concentration of 0.025 mg ml". This is expected because as a sample
becomes purer the more concentrated the active compound becomes. Fraction 0,
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Figure 5.3.3 TLC plate of fractions from the small vacuum column
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D. Thin layer chromatography
The compounds eluted from spots H, I and J displayed a high cyclooxygenase
inhibitory activity. As the bands were overlapping there might have been some














Figure 5.3.4 TLC plate of fraction 0
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Table 5.3.4Cyclooxygenase inhibitory activity displayed by spots offraction O.














E. High performance liquid chromatography
Cyclooxygenase inhibitory activity could only be detected at the peak labelled (a).
This peak was collected and from Figure 5.3.6 it is clear that it is a pure compound.
The noise at the baseline is probably very small quantities of other compounds.
These compounds are, however, in low concentrations. The symmetry of the peak is
an indication of its purity. However, once this peak was separated from the other




































,Figure 5.3.6 Ultraviolet spectrum of the active peak
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Figure 5.3.7 HPLC chromatogram of fraction I
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"
Figure 5.3.8 HPLC chromatogram of fraction J
No cyclooxygenase inhibitory activity could be detected in any of the fractions
collected. The chromatograms of samples I and J show that there are a number of
compounds in each of these fractions but once these compounds are separated the
cyclooxygenase inhibitory activity disappears. The cyclooxygenase inhibitory activity
that I and J displayed could have been as a result of contamination from the
compound(s) in fraction H (Figure 5.3.4).
F. Testing the lack of activity in samples I and J
Samples I and J displayed no cyclooxygenase inhibitory activity for the samples that
was run in 80% and 100% methanol. Peaks were not collected separately and
therefore the inactivity in I and J could not be attributed to the concept of synergism;
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where two or more molecules act together to confer biological activity. Samples I and
J were collected as entire samples without separation of the different compounds
found in them. The lack of activity could therefore be attributed to the molecules
breaking down on the HPLC.
5.4 CONCLUSIONS
The isolation of an anti-inflammatory compound proved to be unsuccessful. Although
the crude extract and some of the extracts obtained from the purification process
displayed considerable activity, the pure compound that was obtained had no
cyclooxygenase inhibitory activity. Itwas determined that the active compounds break
down on the HPLC.
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CHAPTER SIX
SCREENING FOR ANTI-BACTERIAL ACTIVITY
6.1 INTRODUCTION
Anton van Leeuwenhoek was the first to describe microscopic "streaks and threads" . In
1850 Casmir Dawaine characterized these microscopic organisms as bacteria
(ALCAMO, 1994). It was only as the twentieth century unfolded that scientists realized
that we live in the center of a microbial universe.
Bacteria are prokaryotes and are amongst the most abundant organisms on earth. They
have adapted to more different living conditions than any other group of organisms. They
inhabit the air, soil and water and exist in enormous numbers on the surfaces of virtually
all plants and animals. On all sides microscopic organisms surround us and make their
presence felt for good or bad. The useful species outnumber the harmful species by far
and are of such value to humans that we cannot live without them . The remaining
species are agents of disease and death.
A. Disease causing bacteria
Bacteria have been involved in the great plagues of history and still are today . Bacteria
found in the air, soil and water all cause a wide array of diseases in humans some
of which are curable and some not. Table 6.1.1 shows some of these diseases.
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Table 6.1.1 Airborne, waterborne, foodborne and soilborne bacterial diseases
(ALCAMO,1994)
Disease Causative agent Descrirtion of agent
Airborne bacterial Strep throat Streptococcus Gram positive,
diseases pyogenes streptococcus
Diphtheria Corynebacterium Gram positive, rod
diphetria
Whopping cough Bordella pertussis Gram negative, rod
Meningococcal Neisseria meningtidis Gram negative,
meningitis diplococcus
Haemophilus Haemophilus Gram negative, rod
meningitis influenzae b
Tuberculosis Mycobacterium Acid-fast, rod
tuberculosis
Pneumococcal Streptococcus Gram positive,
pneumonia pneumoniae diplococcus
Klebsiella pneumonia Klebsiella Gram negative, rod
pneumoniae
Primary atypical Mycoplasma Mycoplasma
pneumonia pneumoniae
Serratia pneumonia Serratia marcescens Gram negative, rod
Legionnaires' disease Legionella Gram negative, rod
pneumophila
Q fever Coxiella burnetti Rickettsia
Psittacosis Chlamydia psittaci Chlamydia
Chlamydial Chlamydia Chlamydia
Waterborne and Botulism Clostridium botulinum Gram positive, rod
foodborne diseases
Staphylococcal food Staphylococcus Gram positive,
poisoning aureus staphylococcus
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Disease Causative agent Description of agent
Clostridial food Clostridium Gram positive, rod
poisoning perfringens
Salmonellosis Salmonella typhi Gram negative, rod
Shigellosis Shigella Gram negative, rods
Cholera Vibrio cholerae Gram negative, curved rod
Infantile and Escherichia coli Gram negative, rod
traveller's diarrhea
Brucellosis Brucella species Gram negative, rod
Campylobacteriosis Campylobacter jejuni Gram negative, rod
Soilborne bacterial Anthrax Bacillus anthracis Gram positive, rod
diseases
Tetanus Clostridium tetani Gram positive, rod




Listeriosis Listeria Gram positive, rod
monocytogenes
Mellioidosis Pseudomonas Gram negative, rod
gseudomallei
B. Anti-bacterial agents
More than 50 years have passed since the modern antibiotic era had the first clinical
trial for penicillin in 1941. Medicine has since been transformed and the use of
antibiotics has grown to enormous proportions.
The bulk of natural antibiotics have been isolated from soil microorganisms. It is
estimated that about 5 000 to 10 000 natural antibiotics have been isolated and
characterized and approximately 50 000 to 100 000 analogues have been synthesized
but most of these compounds do not have any medicinal value (MITSCHER, DRAKE,
GOLLAPUDI & OKWUTE, 1987).
99
The most important and frequently used antibiotics are shown in Table 6.1.2.












































Most antibiotics act on the cell wall. They break down the cell wall of the bacterium
cells, releasing all the cell contents. This inhibits the bacterial cells from reproducing
and hence destroys the disease (ALCAMO, 1994).
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6.2 MATERIALS AND METHODS
A. Extraction of plant material
Extraction was carried out as in Section 4.2.2 (B). The residues were resuspended in
ethyl acetate, ethanol and water, respectively, to a final concentration of 100 mg m1"1.
The antibacterial bioassay was carried out using these extracts.
B. Anti-bacterial Activity
Inhibition of bacterial growth by plant extracts was investigated using the disc diffusion
assay (RASOANAIVO & RATSIMAMANGA-UVERG, 1993). The following bacteria were
used; Staphylococcus aureus, Staphylococcus epidermis, Micrococcus luteus,
Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa. All bacteria
were maintained at 4 QC on nutrient agar plates.
Base plates were prepared by pouring 10 ml Mueller-Hinton (MH) agar (Biolab) into
sterile petri-dishes. Molten MH agar held at 48 QC was inoculated with a broth culture
(106 - 108 bacteria per ml) of the test organism and poured over the base plates. Ten
~I of plant extract was applied per filter paper disc (6 mm diameter, Whatman no.3)
resulting in a final concentration per disc of 1 mg plant extract. The discs were air dried
and placed onto the top layer of the agar. Each extract was tested in quadruplicate (4
discs per plate) with a neomycin disc (200 ~g or 500 ~g) as a reference. The plates
were incubated for 18-24 hr at room temperature. Antibacterial activity was expressed
as a ratio of the inhibition zone produced by the plant extract and the inhibition zone
produced by the neomycin reference.
C. Thin Layer Chromatography
Ten ~I of the crude ethyl acetate and ethanol plant extracts (20 mg rnl') of E. caffra, E.
. Iysistemon and E. latissima were spotted onto a 20x20 cm glass 0.25 mm Merck silica
gel TLC plate. The plate was developed in hexane : ethyl acetate 2:1 (v/v). Spots that
were visible under normal and ultraviolet light, (254 and 366 nm) were demarcated. The
spots were tested for anti-bacterial activity using the bioautographic bioassay.
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D. Bioautographic bioassay
The bioa utographic bioassay was performed according to a method by SLUSARENKO,
LONGLAND & WHITEHEAD (1989). An overnight culture of Staphylococcus aureus
was pelleted by centrifugation at 3000 g (Beckman Avanti J-25 I). The pellet was
resuspended in 2 ml of the supernatant. This bacterial suspension was added to 25 ml
of molten Mueller Hinton agar (Biolab) supplemented with 1% (v/v) glycerol and 0,1%
(w/v) 2,3,5-triphenyltetrazolium chloride (Sigma) . This was poured over a TLC plate
containing crude ethyl acetate and ethanolic extracts of E. caffra, E. latissima and E.
Iysistemon . After the medium had solidified the overlayed TLC plate was placed in a
box lined with moist tissue paper and incubated overnight at 37 DC.
4.3 RESULTS AND DISCUSSION
A. Anti-bacterial activity
The results of the screening for anti-bacterial activity are presented in Table 6.3.1. In
general the leaves displayed very little activity; with no activity in the ethyl acetate and
ethanol extracts for all the species. The water extracts of E. caffra, E. humeana, E.
latissima and E. zeyheri displayed some activity. The bark was more active than the
leaves; displaying activity in all three solvent extracts.
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TABLE 6.3.1 Anti-bacterial activity of indigenous Erythrina species
Species Plant Solvent used Bacterial strains used
part for
extraction S.a. S.e. B.s. M.I. E.c. K.p. P.a.
E. caffra Leaf Ethyl acetate 0 0 0 0 0 0 0
Ethanol 0 0 0 0 0 0 0
Water 0 0.88 0.44 0.61 0 0 0.63
Bark Ethyl acetate 0.73 0.94 0 0.53 0 0 0.7
Ethanol 0.83 0.59 0 0.69 0 0 0
Water 0 0.79 0 0.45 0 0 0.62
E. humeana Leaf Ethyl acetate 0 0 0 0 0 0 0
Ethanol 0 0 0 0 0 0 0
Water 0 0.7 0 0.62 0 0 0.61
Bark Ethyl acetate 0 0 0.36 0.79 0 0 0
Ethanol 0.89 0 0 0 0.63 0 0
Water 0 0 0 0.7 0 0 0
E. latissima Leaf Ethyl acetate 0 0 0 0 0 0 0
Ethanol 0 0 0 0 0 0 0
Water 0.77 0 0 0 0.6 0 0
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Species Plant Solvent used Bacterial strains used
part for
extraction S.a. S.e. B.s. M.1. E.c. K.p. P.a.
Bark Ethyl acetate 0.88 0 0.31 0.52 0 0 0
Ethanol 0.85 0 0.52 0.55 0 0 0
Water 0 0 0 0.61 0 0 0
E./ysistemon Leaf Ethyl acetate 0 0 0 0 0 0 0
Ethanol 0 0 0 0 0 0 0
Ethanol 0 0 0 0 0 0 0
Bark Ethyl acetate 0.88 0 0.38 0.65 0 0 0
Ethanol 0.68 0 0.37 0.7 0 0 0
Water 0.83 0 0.45 0.65 0 0 0
E. zeyheri Leaf Ethyl acetate 0 0 0 0 0 0 0
Ethanol 0 0 0 0 0 0 0
Water 0.88 0 0 0 0 0 0
Bacteria: 5.a., Staphylococcus aureus, 5.e., Staphylococcus epidermis, B.a., Bacillus subtilis, M.I., Micrococcus luteus, E.c., Escherichia coli, K.p., Klebsiella pneumonia,
P.a., Pseudomonas aeruginosa.
The antibacterial activity is expressed as a ratio of the inhibition zone of the extract (1 mg ml ") to the inhibition zone of the reference (neomycin 200-500 mg rnl")
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\ Activity was mainly detected against the Gram positive bacteria. This is to be expected
as the growth of Gram negative bacteria is more difficult to inhibit. P. aeruginosa was
the only Gram negative bacterium whose growth was inhibited with more than one
extract. It was very interesting that the water extract of E. latissima inhibited the growth
of E. coli. Although there was some inhibition of the Gram negative bacteria, the
inhibitory activity displayed by the extracts was very low. Considerable inhibitory activity
was displayed against Gram positive S. aureus and S. epidermis.
Hexane extracts from E. sigmoidea was found to have anti-bacterial activity against S.
aureus. Erythrabyssin I1 was isolated from this species and found to have anti-bacterial
activity against S. aureus and anti-fungal activity against Aspergillus fumigatus and
Cryptococcus neoformans (NKENGFACK,VUOFFO, VARDAMIDES & FOMUM, 1994).
Sigmoidin A and B, isolated from E. sigmoidea was found to have activity against S.
aureus and M. luteus (BIYITI, PESANDO & PUISEUX-DAO, 1988). Eriothrin Band
erybraedins A and C, isolated from E. eriotricha showed anti-bacterial activity against
S. aureus (NKENGFACK, VARDAMIDES, FOMUM & MEYER, 1995).
In a recent report it was shown that bidwillon Band auriculatin, isolated from E. x
bidwi/li had anti-bacterial activity against Fusobacterium nucleatum and Prevotella
intermedia (IINUMA, TANAKA, M/ZUNO, YAMAMOTO, KOBAYASHI & YONEMORI,
1992).
A report by M/TSCHER, DRAKE, GOLLAPUDI & OKWUTE (1987) stated that the bark
of E. berteroana, E. crista-ga/li and E. variegata displayed anti-bacterial activity against
S. aureus and M. smegmatis. They also found that the roots of E. costaricans, E.
fusca, E. indica and E. mildbraedii displayed anti-bacterial activity against the same
bacterial strains.
KOUAM, NKENGFACK & FOMUM (1991) reported that n-octacosanyl-4-hydroxy-3-
methoxycinnamate, 6,3-diprenylgenistein and auriculatin from E. senegalensis,
E. excelsa and E. eriotricha displayed activity against S. aureus. They also reported
that these compounds displayed antirhymic effects as cardiovascular agents and anti-
fungal activity against Cladosporium herbarum.
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E. caffra E. Iysistemon E. latissima
Figure 6.3.1 TLC separation of ethyl acetate and ethanol bark extracts of E.
caffra, E. Iysistemon and E. latissima.
• Spots with anti-bacterial activity against S. aureus
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From the TLC results (Figure 6.3.1) it is evident that there are few compounds with a
I
substantial amount of anti-bacterial activ ity especially in E. Iysistemon. There appears
to be no anti-bacterial activity in the E. caffra extracts and only activity at one spot in
the E. latissima extracts.
6.4 CONCLUSIONS
Bark extracts have more anti-bacterial activity than the leaf extracts specifically the
bark of E. caffra and E. Iysistemon. Anti-bacterial activity was mainly against the Gram
positive bacteria especially S. aureus and M. luteus. The bark of E. Iysistemon
appears to be the most active against S. aureus (Figure 6.3.1). It therefore appears to
be a good source of anti-bacterial compounds.
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CHAPTER SEVEN
ISOLATION OF ANTI-BACTERIAL COMPOUNDS FROM THE
BARK OF E. Iysistemon
7.1 INTRODUCTION
Bacteria have a short doubling time if there is sufficient resources available. The basic
structure of bacteria allows it to reproduce rapidly. This rapid reproduction process
makes the DNA of the bacterium cell prone to mutation. The origination of a new
bacterial strain is therefore an event that occurs frequently. With the advent of new
bacterial strains many existing anti-bacterial compounds and substances are found to
be less efficient. Even penicillin is no longer able to knock out previously susceptible
micro-organisms. There is therefore a growing need to find new anti-bacterial
compounds and for the design of new anti-bacterial drugs.
From Table 2.3.2 it is clear that the genus Erythrina is a fairly good source of anti-
bacterial compounds. The results from Chapter 6 show that E. Iysistemon has a few
anti-bacterial compounds that are active against S. aureus (Figure 6.3.2). It is therefore
a worthy undertaking to isolate anti-bacterial compounds from this plant.
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7.2 MATERIALS AND METHODS
To isolate active compounds bioassay guided fractionation was carried out. Figure 7.2.1
is a summary of the methods used in the purification process.






High performance liquid chromatography
Figure 7.2.1 Flow diagram of methods used in compound isolation
A. Bulk extraction
One kg of dried bark of E. Iysistemon was cut into 1x1 cm pieces. These pieces of bark
were placed into a Soxhlet apparatus and extracted with 2.5 I of ethanol for 30 hours.
B. Vacuum liquid chromatography
Four grams of the ethanolic extract was dried under vacuum and placed onto a Merck
silica (150 g) vacuum column (30x6 cm). Compounds were eluted with 400 ml
hexane : ethyl acetate. A solvent gradient was used consisting of 100% : 0% to
0% : 100% (v/v) hexane : ethyl acetate, in 5% steps. Four hundred ml fractions were
collected and dried under vacuum. The residues were resuspended with acetone to a
final concentration of 10 mg rnl' and tested for anti-bacterial activity using the microtitre
bioassay. Ten ~I of each of these fractions were spotted onto a 20x10 cm plastic Merck
silica gel TLC plate. The TLC plate was developed in hexane : ethyl acetate 2 : 1 (v/v).
C. Microtitre bioassay
Anti-bacterial activity was determined using the microtitre bioassay (ELOFF, 1998).
The test solution (plant extract) was serially diluted 50% with water (30 ~I plant extract
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+ 30 1-11 water). An equal amount of an overnight culture of S. aureas that had been
diluted 100 fold was added to each well. The microplate was then covered and
incubated at 37 QC overnight. To indicate bacterial growth 40 IJI of 0.2 rnq rnl" p-
indonitritetrazolium viole t was added to each well. After this addition the microplate was
incubated at 30 QC for 30 min. Dilutions of neomycin served as a positive control. The
other controls that were used was broth with no bacteria, bacterial solution with no test
solution and the highest concentration of the solvent used to resuspend the plant
residues.
D. Chromatotron
The sample that displayed anti-bacterial activity was dried under vacuum and the
residue was placed onto a 2 mm chromatotron plate. The plate was developed in a
solvent gradient consisting of 100% : 0% to 70% : 30% (v/v) benzene: ethyl acetate, in
10% steps. The total volume of the solvent mixture was 100 ml. Twenty ml fractions
were collected. Ten 1-11 of each of these fractions were spotted onto a 20x1 0 cm plastic
Merck silica gel TLC plate. The TLC plate was developed in benzene: ethyl acetate
3 : 1 (v/v).
E. High performance liquid chromatography
The fraction that displayed anti-baterial activity was purified further on a Varian (5000)
HPLC. The sample was run on a C-18 semi-preparative Phenomenex column
(250x10 mm) in 80% : 20% (v/v) acetonitrile: water. The different compounds present
in the samples were detected with a uv 3000HR detector at 200 nm. The flow rate was
2.5 ml min'.
F. Identification of biologically active compound
Proton and carbon NMR spectra of the active fractions were run. This was done by
Professor D. Mulholland at the Department of Chemistry at the University of Natal,
Durban.
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7.3 RESULTS AND DISCUSSION
A. Vacuum liquid chromatography
From the TLC analysis (Figure 7.3.1) of the fractions from the vacuum column it is clear
that each of the fractions contains different compounds. Fraction G appeared to be
relatively clean with a single spot appearing in the hexane : ethyl acetate separation.
Figure 7.3.2 clearly indicated that the only fraction with anti-bacterial activity was fraction
G. The first two wells of lane 7 showed no pink or red discoloration indicating anti-
bacterial activity. The MIC of fraction G was 0.075 mg ml'. The MIC of this fraction was
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Figure 7.3.1 TLC plate of fractions from the vacuum column
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Figure 7.3.2 Microplate showing anti-bacterial activity of fractions from the vacuum column. Fractions A-M were placed into
wells 1-13, respectively. Wells 14-17 were the controls (well 14 - acetone control, well 15 - neomycin control, well 16 - broth
control and well 17 - bacteria control).
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B. Chromatotron
' Figure 7.3.5 showed that the fractions collected from the chromatotron were fairly pure
with single spots appearing in fractions A, 8 and C in the benzene : ethyl acetate
separation . The spots appeared in the same general region but the Rf values of the
spots were different indicating that they are different compounds. The spot of fraction
B displayed a brown colour when viewed under normal light indicating that it was













Figure 7.3.3 TLC plate of fractions from the chromatotron
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Figure 7.3.4 Microplate showing anti-bacterial activity of fractions from the
chromatotron. Fractions A-E were placed into wells 1-5, respectively. Wells 6-9
were the controls (well 6 - acetone control, well 7 - neomycin control, well 8 •
broth control and well 9 - bacteria control).
The microplate clearly showed that fraction B has the most anti-bacterial activity.
Fraction C also showed activity but fraction B inhibited bacterial growth at a lower
concentration. The MIC for fraction B was 0.0375 mg ml", The MIC had clearly
decreased from the initial one which is expected because as the sample becomes purer
the active compound becomes more concentrated. Although the MIC was low it was not
as low as that of the neomycin which was 0.00125 mg ml",
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C. High performance liquid chromatography
The chromatogram showed a single major peak with smaller peaks on either side of the
major peak. Since the other peaks were so small it was logical to assume that they
occurred in small quantities and that the concentration was to low to confer any anti-
bacterial activity. Figure 7.3.6 shows that the major peak is relatively symmetrical which
is an indication of its purity.
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,Figure 7.3.6 Ultraviolet spectrum of active compound
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D. Identification of the active compound
By comparing the carbon and proton NMR to a previous study by HASHIDOKO,










Synonyms : Erythrinin B, 6-lsopentenylgenistein and 4', 5, 7-Trihydroxy-6-
prenylisoflavone
Physical descriptio~ : Bright-yellow plates
Molecular formula: C2oH1S0S
Molecular weight: M 338.359
'Melt ing point: Mp 220-221 °c
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One hundred and twenty mg of wighteone was isolated from the bark of E. Iysistemon
and the MIC of this compound was 0.038 mg rnl'. The large quantity of this compound
indicates that it is by no means a new compound.
This isoflavone had previously been isolated from the bark of E. variegata
(DESHPANDE, PENDSE & PENDSE, 1977). It was previously reported that it is used
as a phytoalexin. Never before has it been reported to display anti-bacterial activity. This
investigation did, however, show that it does display anti-bacterial activity against the
Gram positive bacterium, S. aureus .
S. aureus is known as the bacterium involved in food poisoning (Table 6.1.1). The food
industry is one of the biggest industries worldwide, if not the biggest. There is therefore
always a search to improve foods in terms of taste and preservation. The need to keep
food free of bacterial growth is an important issue within the food market. It is one that
receives ongoing funding and research. The anti-bacterial activity displayed by
Wighteone against S. aureus could very well be the answer to Staphylococcal food
poisoning. Wighteone is not a wonder drug but it could be used as a template for drug
design or further investigations into compounds and drugs against Staphylococcal food
poisoning.
7.4 CONCLUSIONS
The chromatographic methods used in this investigation proved to be successful as an
anti-bacterial compound was isolated from the bark of E. Iysistemon.
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CHAPTER EIGHT
GENERAL DISCUSSION AND CONCLUSIONS
8.1 DISCUSSION AND CONCLUSIONS
The phytochemical analysis (Chapter 3) revealed that the Erythrina species indigenous
to South Africa contains all the important secondary compounds (alkaloids, f1avonoids,
coumarins and triterpenes) that are found elsewhere in this genus. The TLC analysis
brought to the forefront further similarities between E. caffra and E. Iysistemon. These
two species appear to have similar chemical profiles for the flavonoid, triterpene and
coumarin detection. This is in addition to the morphological similarities that already exist
between these two species.
A literatu re search showed that the roots, bark and leaves of these trees are used by
traditional healers to cure ailments such as earache, toothache, sprains, strained
ligaments, to disinfect wounds and for venereal diseases to mention but a few (Table
2.3.1). The screening investigation (Chapters 4 and 6) validated the use of the bark and
leaves of Erythrina species indigenous to South Africa by traditional healers for
inflammation and bacterial infection. The bark displayed higher anti-inflammatory and
anti-bacterial activity than the leaves, specifically the bark of E. caffra and E. Iysistemon.
These two species are also the most widely used of the species indigenous to South
Africa by traditional healers. The bark being used more frequently than the leaves.
The screening results (Chapters 4 and 6) demanded further investigation in terms of
compound isolation for both anti-inflammatory and anti-bacterial activity. The anti-
inflammatory compound isolation proved to be unsuccessful. This proved to be a
cumbersome, frustrating process as drug discovery usually is. There has only been one
report of an anti-inflammatory compound isolated from this genus (Table 2.3.2). This is
in contradiction to the number of anti-bacterial compounds that have been isolated.
Although the number of anti-bacterial compounds that have been isolated is small it
does exceed the number of anti-inflammatory compounds by far (Table 2.3.2). The anti-
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bacterial compounds that have been isolated from this genus (Table 2.3.2) appear to
have activity against Gram positive bacteria, specifically S. aureus. The biologically
active compounds appear to be flavonoids or derivatives of this family of compounds like
isofJavones. The anti-bacterial compound (Wighteone) isolated from the bark of E.
Iysistemon is a prenylated isofJavone. Since there is a pronounced presence of
flavonoids in the bark of Erythrina species indigenous to South Africa (Figure 3.3.5) one
cannot help but wonder how many biologically active compounds can be extracted and
isolated from Erythrina species indigenous to South Africa. The isolation of the anti-
bacterial compound, Wighteone is by no means a major drug discovery but it does
provide a new use for the compound. Drug discovery is a long and expensive process
involving a lot more than is required for a Masters research project (Figure 1.3.1). Drug
discovery from plants is, however not an impossibility (Table 1.3.2) and the need for
drug discovery cannot be emphasized enough. In a world where disease, illness and
death are the order of the day there is an overwhelming need for research of this nature
to continue, on a larger scale.
8.2 FUTURE PROSPECTS
The nature of science is always to ask "how, why, when and where?". Finding or
discovering something always raises more questions. A research project in reality has
no end and this one has been no exception.
The use of TLC analysis should be explored to test for the presence of other types of
compounds in the Erythrina species indigenous to South Africa. Chemical profiles of all
the different plant organs should be developed and these profiles should be used as a
chemo-taxonomic key to identify and distinguish between species.
The phytochemical analysis (Chapter 3) indicated the presence of alkaloids, fJavonoids,
triterpenes and coumarins. This analysis did, however not reveal specific chemical
names of the individual compounds. Isolation of these compounds and an attempt to
identify them would be a valuable project.
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Literature showed that the genus Erythrina has a lot of biological activity. It has even
been shown that some of the Erythrina species have anti-HIV activity (Table 2.3.2). It
would therefore be interesting to screen the roots, bark and leaves for other types of
biological activity, such as anti-hypertension, anti-cancer, anti-HIV, anti-malarial and
anti-amoebic activity. Table 2.2.1 shows that quite a number of compounds have been
isolated from this genus but Table 2.3.2 shows that very few of the compounds have
biological activity. None of the compounds that have previously been isolated from the
Erythrina species indigenous to South Africa have been reported to have biological
activity. Therefore testing compounds that have been previously isolated for biological
activity would be advisable.
Lastly it would be interesting to determine if the isolated anti-bacterial compound
(Wighteone) is found in any of the other species indigenous in South Africa and whether
it is only in the bark or also in the leaves.
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We shall not cease from exploration
And at the end of all our exploring
Will be to arrive where we started
And know the place for the first time
T.S. Elliot
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